

SPARTON CORP
Form 10-Q
February 09, 2011
Table of Contents

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

x **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the quarterly period ended December 31, 2010

Or

.. **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the transition period from _____ to _____

Commission File Number 1-1000

Sparton Corporation

(Exact name of registrant as specified in its charter)

Edgar Filing: SPARTON CORP - Form 10-Q

Ohio
(State or other jurisdiction of
incorporation or organization)

38-1054690
(I.R.S. Employer
Identification No.)

425 N. Martingale Road, Suite 2050, Schaumburg,

Illinois
(Address of principal executive offices)

60173-2213
(Zip code)

(847) 762-5800
(Registrant's telephone number, including zip code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or such shorter period that the registrant was required to submit and post such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer Accelerated filer
Non-accelerated filer (Do not check if a smaller reporting company) Smaller reporting company
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

As of January 31, 2011, there were 10,216,484 shares of common stock, \$1.25 par value per share, outstanding.

Table of Contents

TABLE OF CONTENTS

| | | |
|----------|--|----|
| PART I | <u>FINANCIAL INFORMATION</u> | 3 |
| ITEM 1. | <u>FINANCIAL STATEMENTS</u> | 3 |
| | <u>CONDENSED CONSOLIDATED BALANCE SHEETS AS OF DECEMBER 31, 2010 AND JUNE 30, 2010 (UNAUDITED)</u> | 3 |
| | <u>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS FOR THE THREE AND SIX MONTHS ENDED DECEMBER 31, 2010 AND 2009 (UNAUDITED)</u> | 4 |
| | <u>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE SIX MONTHS ENDED DECEMBER 31, 2010 AND 2009 (UNAUDITED)</u> | 5 |
| | <u>CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY FOR THE SIX MONTHS ENDED DECEMBER 31, 2010 AND 2009 (UNAUDITED)</u> | 6 |
| | <u>NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</u> | 7 |
| ITEM 2. | <u>MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</u> | 21 |
| ITEM 3. | <u>QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</u> | 35 |
| ITEM 4. | <u>CONTROLS AND PROCEDURES</u> | 35 |
| PART II | <u>OTHER INFORMATION</u> | 36 |
| ITEM 1. | <u>LEGAL PROCEEDINGS</u> | 36 |
| ITEM 1A. | <u>RISK FACTORS</u> | 36 |
| ITEM 6. | <u>EXHIBITS</u> | 37 |
| | <u>SIGNATURES</u> | 38 |
| | <u>CERTIFICATIONS</u> | |

Table of Contents**PART I. FINANCIAL INFORMATION****Item 1. Financial Statements.**

SPARTON CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(UNAUDITED)

(Dollars in thousands, except share data)

| | December 31, 2010 | June 30, 2010 (a) |
|--|----------------------|----------------------|
| Assets | | |
| Current Assets: | | |
| Cash and cash equivalents | \$ 29,941 | \$ 30,589 |
| Restricted cash | | 3,162 |
| Accounts receivable, net of allowance for doubtful accounts of \$455 and \$532, respectively | 18,504 | 17,967 |
| Inventories and cost of contracts in progress, net | 35,076 | 26,514 |
| Income taxes receivable | 304 | 296 |
| Deferred income taxes | 57 | 57 |
| Property held for sale | 3,900 | 3,900 |
| Prepaid expenses and other current assets | 1,988 | 1,449 |
| Total current assets | 89,770 | 83,934 |
| Property, plant and equipment, net | 10,179 | 8,924 |
| Goodwill | 19,141 | 19,141 |
| Other intangible assets, net | 4,583 | 4,803 |
| Other non-current assets | 2,949 | 3,059 |
| Total assets | \$ 126,622 | \$ 119,861 |
| Liabilities and Shareholders Equity | | |
| Current Liabilities: | | |
| Current portion of long-term debt | \$ 121 | \$ 121 |
| Accounts payable | 14,462 | 13,045 |
| Accrued salaries and wages | 4,177 | 5,737 |
| Accrued health benefits | 948 | 989 |
| Current portion of pension liability | 178 | 1,139 |
| Restructuring accrual | 170 | 233 |
| Advance billings on customer contracts | 22,773 | 21,595 |
| Other accrued expenses | 3,849 | 3,345 |
| Total current liabilities | 46,678 | 46,204 |
| Deferred income taxes non-current | 1,807 | 1,579 |
| Pension liability non-current portion | 2,080 | 1,980 |
| Long-term debt non-current portion | 1,735 | 1,796 |
| Environmental remediation non-current portion | 3,886 | 4,033 |
| Total liabilities | 56,186 | 55,592 |
| Commitments and contingencies | | |

Edgar Filing: SPARTON CORP - Form 10-Q

Shareholders' Equity:

| | | |
|--|-------------------|-------------------|
| Preferred stock, no par value; 200,000 shares authorized, none outstanding | | |
| Common stock, \$1.25 par value; 15,000,000 shares authorized, 10,216,484 and 10,200,534 shares outstanding, respectively | 12,771 | 12,751 |
| Capital in excess of par value | 20,216 | 19,864 |
| Retained earnings | 40,541 | 35,026 |
| Accumulated other comprehensive loss | (3,092) | (3,372) |
| Total shareholders' equity | 70,436 | 64,269 |
| Total liabilities and shareholders' equity | \$ 126,622 | \$ 119,861 |

(a) Derived from the Company's audited financial statements as of June 30, 2010.

See Notes to unaudited condensed consolidated financial statements.

Table of Contents

SPARTON CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(UNAUDITED)

(Dollars in thousands, except share data)

| | For the Three Months Ended | | For the Six Months Ended | |
|--|----------------------------|----------------------|--------------------------|----------------------|
| | December 31, 2010 | December 31, 2009 | December 31, 2010 | December 31, 2009 |
| Net sales | \$ 46,331 | \$ 47,223 | \$ 92,098 | \$ 95,327 |
| Cost of goods sold | 38,784 | 39,088 | 77,525 | 79,820 |
| Gross profit | 7,547 | 8,135 | 14,573 | 15,507 |
| Operating Expense: | | | | |
| Selling and administrative expenses | 5,689 | 5,109 | 10,523 | 9,689 |
| Internal research and development expenses | 155 | | 282 | |
| Amortization of intangible assets | 110 | 117 | 220 | 234 |
| Restructuring/impairment charges | | 1,007 | 77 | 1,883 |
| Gain on acquisition | | | (2,400) | |
| Gain on sale of property, plant and equipment | | | (18) | |
| Other operating expenses | 12 | 423 | 204 | 613 |
| Total operating expense | 5,966 | 6,656 | 8,888 | 12,419 |
| Operating income | 1,581 | 1,479 | 5,685 | 3,088 |
| Other income (expense) | | | | |
| Interest expense | (181) | (203) | (351) | (462) |
| Interest income | 28 | 8 | 86 | 16 |
| Other, net | 121 | 35 | 195 | 116 |
| Total other expense, net | (32) | (160) | (70) | (330) |
| Income before provision for (benefit from) income taxes | 1,549 | 1,319 | 5,615 | 2,758 |
| Provision for (benefit from) income taxes | 114 | (1,929) | 100 | (1,895) |
| Net income | \$ 1,435 | \$ 3,248 | \$ 5,515 | \$ 4,653 |
| Income per share of common stock: | | | | |
| Basic | \$ 0.14 | \$ 0.33 | \$ 0.54 | \$ 0.47 |
| Diluted | \$ 0.14 | \$ 0.33 | \$ 0.54 | \$ 0.47 |
| Weighted average shares of common stock outstanding: | | | | |
| Basic | 10,209,376 | 9,964,420 | 10,204,955 | 9,957,964 |
| Diluted | 10,249,593 | 9,964,420 | 10,229,449 | 9,957,964 |

Edgar Filing: SPARTON CORP - Form 10-Q

See Notes to unaudited condensed consolidated financial statements.

Table of Contents**SPARTON CORPORATION AND SUBSIDIARIES****CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS****(UNAUDITED)**

(Dollars in thousands)

| | For the Six Months Ended | |
|---|---------------------------------|---------------------|
| | December 31, | December 31, |
| | 2010 | 2009 |
| Cash Flows from Operating Activities: | | |
| Net income | \$ 5,515 | \$ 4,653 |
| Adjustments to reconcile net income to net cash provided by operating activities: | | |
| Depreciation and amortization | 687 | 739 |
| Deferred income tax expense | 228 | (1,895) |
| Pension expense | 285 | 723 |
| Stock-based compensation expense | 372 | 384 |
| Non-cash restructuring/impairment charges | | 150 |
| Net gain on sale of property, plant and equipment | (18) | |
| Gain on acquisition | (2,400) | |
| Other | 174 | 102 |
| Changes in operating assets and liabilities: | | |
| Accounts receivable | (537) | 16,423 |
| Income taxes receivable | (8) | |
| Inventories and cost of contracts in progress | 2,094 | 6,547 |
| Prepaid expenses and other assets | (598) | (976) |
| Advance billings on customer contracts | 1,178 | (5,421) |
| Accounts payable and accrued expenses | (954) | (20,534) |
| Net cash provided by operating activities | 6,018 | 895 |
| Cash Flows from Investing Activities: | | |
| Purchase of certain contract manufacturing assets of Delphi Medical | (8,419) | |
| Additional goodwill from SMS acquisition | | (977) |
| Change in restricted cash | 3,162 | (3,129) |
| Purchases of property, plant and equipment | (1,362) | (687) |
| Proceeds from sale of property, plant and equipment | 18 | 450 |
| Net cash used in investing activities | (6,601) | (4,343) |
| Cash Flows from Financing Activities: | | |
| Net short-term bank borrowings (repayments) | | (15,500) |
| Repayment of long-term debt | (65) | (4,457) |
| Payment of debt financing costs | | (844) |
| Net cash used in financing activities | (65) | (20,801) |
| Net decrease in cash and cash equivalents | (648) | (24,249) |
| Cash and cash equivalents at beginning of period | 30,589 | 36,261 |
| Cash and cash equivalents at end of period | \$ 29,941 | \$ 12,012 |
| Supplemental disclosure of cash flow information: | | |
| Cash paid for interest | \$ 182 | \$ 329 |

Edgar Filing: SPARTON CORP - Form 10-Q

| | | | |
|---------------------------------------|----------|----|---|
| Cash paid (received) for income taxes | \$ (102) | \$ | 4 |
|---------------------------------------|----------|----|---|

See Notes to unaudited condensed consolidated financial statements.

Table of Contents

SPARTON CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY

(UNAUDITED)

(Dollars in thousands, except share data)

| | Six Months Ended December 31, 2010 | | | | | |
|--------------------------------------|------------------------------------|-----------|--------------------------------------|----------------------|---|--------------|
| | Common Stock | | Capital In Excess of Par Value | Retained Earnings | Accumulated Other Comprehensive Income (Loss) | Total |
| | Shares | Amount | | | | |
| Balance at June 30, 2010 | 10,200,534 | \$ 12,751 | \$ 19,864 | \$ 35,026 | \$ (3,372) | \$ 64,269 |
| Stock grants issued | 15,950 | 20 | (20) | | | |
| Stock-based compensation | | | 372 | | | 372 |
| Comprehensive income, net of tax: | | | | | | |
| Net income | | | | 5,515 | | 5,515 |
| Change in unrecognized pension costs | | | | | 280 | 280 |
| Comprehensive income | | | | | | 5,795 |
| Balance at December 31, 2010 | 10,216,484 | \$ 12,771 | \$ 20,216 | \$ 40,541 | \$ (3,092) | \$ 70,436 |

| | Six Months Ended December 31, 2009 | | | | | |
|--------------------------------------|------------------------------------|-----------|--------------------------------------|----------------------|---|--------------|
| | Common Stock | | Capital In Excess of Par Value | Retained Earnings | Accumulated Other Comprehensive Income (Loss) | Total |
| | Shares | Amount | | | | |
| Balance at June 30, 2009 | 9,951,507 | \$ 12,439 | \$ 19,671 | \$ 27,586 | \$ (4,801) | \$ 54,895 |
| Stock grants issued | 27,000 | 34 | (34) | | | |
| Stock-based compensation | | | 384 | | | 384 |
| Comprehensive income, net of tax: | | | | | | |
| Net income | | | | 4,653 | | 4,653 |
| Change in unrecognized pension costs | | | | | 637 | 637 |
| Net and comprehensive income | | | | | | 5,290 |
| Balance at December 31, 2009 | 9,978,507 | \$ 12,473 | \$ 20,021 | \$ 32,239 | \$ (4,164) | \$ 60,569 |

See Notes to unaudited condensed consolidated financial statements.

Table of Contents

SPARTON CORPORATION AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(1) Business and Basis of Presentation

Sparton Corporation and subsidiaries (the Company or Sparton) has been in continuous existence since 1900. It was last reorganized in 1919 as an Ohio corporation. The Company is a provider of complex and sophisticated electromechanical devices with capabilities that include concept development, industrial design, design and manufacturing engineering, production, distribution, and field service. The three primary markets the Company serves are the Medical Device (Medical), Defense & Security Systems (DSS), and Electronic Manufacturing Services (EMS) industries. The Company reports its operating results under these three reportable business segments. Financial information by segment is presented in Note 16. All of the Company's facilities are registered to ISO standards, including 9001 or 13485, with most having additional certifications. The Company's products and services include products for Original Equipment Manufacturers (OEM) and Emerging Technology (ET) customers that are microprocessor-based systems that include transducers, printed circuit boards and assemblies, sensors, and electromechanical components, as well as development and design engineering services relating to these product sales. Sparton also develops and manufactures sonobuoys, an anti-submarine warfare (ASW) device, used by the United States Navy and other free-world countries. Many of the physical and technical attributes in the production of sonobuoys are similar to those required in the production of the Company's other electrical and electromechanical products and assemblies.

The unaudited condensed financial statements and related footnotes have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) for interim financial information and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. The financial information presented herein should be read in conjunction with the Company's Annual Report on Form 10-K for the fiscal year ended June 30, 2010, which includes information and disclosures not presented herein. All significant intercompany accounts and transactions have been eliminated in consolidation. Certain reclassifications of prior period amounts have been made to conform to the current year presentation. Subsequent events have been evaluated through the date these financial statements were issued. In the opinion of management, the unaudited condensed consolidated financial statements contain all of the adjustments, consisting of normal recurring adjustments, necessary to present fairly, in summarized form, the consolidated financial position, results of operations and cash flows of the Company. The results of operations for the three and six months ended December 31, 2010 are not indicative of the results that may be expected for the full fiscal year 2011.

(2) Acquisition of Certain Assets of Delphi Medical's Contract Manufacturing Business

On August 6, 2010, the Company completed the acquisition of certain assets related to the contract manufacturing business of Delphi Medical Systems, LLC (Delphi Medical or Delphi). The purchase price was approximately \$8.6 million, including additional consideration paid during the three months ended December 31, 2010 related to determination of the final inventory value. Total cash consideration paid of approximately \$8.4 million, including a \$2.0 million escrowed holdback, was net of approximately \$0.2 million for the assumption of retained employee accruals and was financed entirely through the use of Company cash. The purchase agreement provides for the recovery from Delphi Medical of an amount up to \$2.0 million, deposited in escrow at closing, for certain excess and obsolete inventory remaining on-hand at the end of the 18 month period from closing. These escrowed funds are additionally available for payment of potential seller indemnification obligations in relation to the agreement.

The acquired business, which is reported in the Company's Medical segment, provides a new and diversified customer base and provides Sparton with a geographic presence in the western United States. Delphi Medical primarily manufactures OEM medical devices including blood separation equipment, spinal surgery products and 3-D eye mapping devices. It also provides engineering and manufacturing support to a market-leading environmental sensor company whose markets include meteorology, weather critical operations and controlled environment applications.

Table of Contents

The following table represents the preliminary allocation of the total consideration to assets acquired and liabilities assumed from Delphi Medical based on Sparton's preliminary estimate of their respective fair values (in thousands):

| | |
|---|----------|
| Total purchase consideration: | \$ 8,419 |
| Assets acquired and liabilities assumed: | |
| Inventory | 10,656 |
| Equipment | 360 |
| Employee accruals assumed | (197) |
| Total assets acquired and liabilities assumed | 10,819 |
| Gain on acquisition | \$ 2,400 |

Sparton has determined that the fair value of the assets acquired and liabilities assumed related to this acquisition exceed the total purchase consideration and as a result the Company has recorded a gain on acquisition of \$2.4 million in the three months ended September 30, 2010. Sparton believes it was able to purchase this contract manufacturing business from Delphi Medical significantly below its fair value due to Delphi's desire to liquidate this asset in a timely manner and focus on its core business.

Included in the Company's Condensed Consolidated Statements of Operations for the three and six months ended December 31, 2010 are net sales of approximately \$11.4 million and \$17.3 million, respectively, and income before provision for income taxes of approximately \$1.2 million and \$3.6 million, respectively, resulting from the acquisition of Delphi Medical since August 6, 2010.

The following table summarizes, on a pro forma basis, the combined results of operations of the Company and the acquired contract manufacturing business of Delphi Medical as though the acquisition had occurred as of July 1, 2009. The pro forma amounts presented are not necessarily indicative of either the actual consolidated results had the acquisition occurred as of July 1, 2009 or of future consolidated operating results (in thousands, except per share amounts):

| | For the Three Months Ended | | For the Six Months Ended | |
|---|----------------------------|-------------------|--------------------------|-------------------|
| | December 31, 2010 | December 31, 2009 | December 31, 2010 | December 31, 2009 |
| Net sales | \$ 46,331 | \$ 54,213 | \$ 95,549 | \$ 111,875 |
| Income before provision for (benefit from) income taxes | \$ 1,549 | \$ 1,275 | \$ 5,538 | \$ 2,240 |
| Net income | \$ 1,435 | \$ 3,204 | \$ 5,438 | \$ 4,135 |
| Net income per share - basic | \$ 0.14 | \$ 0.32 | \$ 0.53 | \$ 0.42 |
| Net income per share - diluted | \$ 0.14 | \$ 0.32 | \$ 0.53 | \$ 0.42 |

The Company incurred legal, professional and other costs related to this acquisition aggregating approximately \$0.2 million. These costs were recognized as selling and administrative expenses of approximately \$0.1 million and \$0.1 million in the three months ended September 30, 2010 and June 30, 2010, respectively.

On August 6, 2010 and concurrent with the acquisition of Delphi Medical, the Company entered into leases for two facilities housing the operations of this contract manufacturing business. During the six months ended December 31, 2010, the Company initiated and completed the consolidation of the operations into one facility, and terminated the lease for the building which the Company exited.

Table of Contents**(3) Inventories and Cost of Contracts in Progress**

The following are the approximate major classifications of inventory, net of advance billings and related valuation allowances, at December 31, 2010 and June 30, 2010 (in thousands):

| | December 31, 2010 | June 30, 2010 |
|--|----------------------|------------------|
| Raw materials | \$ 36,658 | \$ 25,693 |
| Work in process | 6,625 | 3,611 |
| Finished goods | 4,979 | 6,790 |
| Total inventory and cost of contracts in progress, gross | 48,262 | 36,094 |
| Inventory to which the U.S. government has title due to advance billings | (10,439) | (7,411) |
| Reserve for obsolescence | (2,747) | (2,169) |
| Total inventory and cost of contracts in progress, net | \$ 35,076 | \$ 26,514 |

(4) Property, Plant and Equipment, Net

Property, plant and equipment, net consists of the following at December 31, 2010 and June 30, 2010 (in thousands):

| | December 31, 2010 | June 30, 2010 |
|--|----------------------|------------------|
| Land and land improvements | \$ 1,235 | \$ 1,235 |
| Buildings and building improvements | 15,021 | 14,514 |
| Machinery and equipment | 13,747 | 12,342 |
| Construction in progress | 384 | 574 |
| Total property, plant and equipment | 30,387 | 28,665 |
| Less accumulated depreciation | (20,208) | (19,741) |
| Total property, plant and equipment, net | \$ 10,179 | \$ 8,924 |

The Company currently has for sale its Bluewater Road property in Albuquerque, New Mexico. The Company classifies this property as Property held for sale. On December 8, 2010, the Company entered into an agreement to sell its Bluewater Road property to Coven Holdings LLC (the Buyer), a New Mexico limited liability company. The total purchase price for the property is \$4.5 million, of which \$1.0 million earnest money is being held in escrow pursuant to the purchase agreement. The earnest money, and the accrued interest thereon, is fully refundable for the period which the Buyer has to review the property. The balance of the purchase price is due at closing. The sale is currently expected to close by February 2011 month end, but Sparton can offer no assurances that the sale will close on the terms described herein, or at all.

(5) Goodwill and Other Intangible Assets

Goodwill represents the excess of purchase price over the fair value of the net assets acquired in conjunction with the Company's purchase of Astro Instrumentation, LLC (Astro) in May 2006.

Intangible assets represent the values assigned to customer relationships acquired in conjunction with the Company's purchase of Astro. The weighted average amortization period, gross carrying amount, accumulated amortization and net carrying value of intangible assets at December 31, 2010 and June 30, 2010 are as follows (in thousands):

Edgar Filing: SPARTON CORP - Form 10-Q

| | Weighted Average Amortization Period | December 31, 2010 | | Net Carrying Value |
|-------------------------------------|---|-----------------------------|-----------------------------|--------------------------|
| | | Gross Carrying Amount | Accumulated Amortization | |
| Amortized intangible assets: | | | | |
| Customer relationships | 180 months | \$ 6,600 | \$ (2,017) | \$ 4,583 |
| June 30, 2010 | | | | |
| | Weighted Average Amortization Period | Gross Carrying Amount | Accumulated Amortization | Net Carrying Value |
| Amortized intangible assets: | | | | |
| Customer relationships | 180 months | \$ 6,600 | \$ (1,797) | \$ 4,803 |

Table of Contents

Sparton did not incur any significant costs to renew or alter the term of its intangible assets during the six months ended December 31, 2010. Amortization expense for each the three months ended December 31, 2010 and 2009 was approximately \$0.1 million. Amortization expense for each the six months ended December 31, 2010 and 2009 was approximately \$0.2 million. Aggregate amortization expense relative to existing intangible assets for the periods shown is currently estimated to be as follows (in thousands):

| Fiscal Year Ended June 30, | |
|-----------------------------------|-----------------|
| 2011 | \$ 440 |
| 2012 | 440 |
| 2013 | 440 |
| 2014 | 440 |
| 2015 | 440 |
| Thereafter | 2,603 |
| Total | \$ 4,803 |

(6) Other non-current assets

Other non-current assets consist of the following at December 31, 2010 and June 30, 2010 (in thousands):

| | December 31, 2010 | June 30, 2010 |
|--|------------------------------|--------------------------|
| Deferred financing fees, net | \$ 536 | \$ 706 |
| Cost method investment in Cybernet Systems Corporation | 1,623 | 1,623 |
| Coors Road long-term lease receivable | 484 | 468 |
| Other | 306 | 262 |
| Total other non-current assets | \$ 2,949 | \$ 3,059 |

Costs incurred in connection with the Company's revolving line-of-credit of approximately \$1.0 million were deferred and are amortized to interest expense over the three year term of the facility.

The Company holds an approximate 12% interest in Cybernet Systems Corporation (Cybernet), a developer of hardware, software, next-generation network computing, and robotics products. Beginning in February 2010, the Company accounts for its investment in Cybernet under the cost method. Previously, this investment was accounted for under the equity method.

The Company is due three equal annual payments, beginning May 1, 2011 and aggregating, approximately \$0.8 million, in relation to the long-term lease of its Coors Road property in Albuquerque, New Mexico. The \$0.8 million of future payments due have been discounted for the imputation of interest, resulting in a discounted receivable of approximately \$0.8 million. Approximately \$0.3 million of this discounted receivable is due within the next 12 months and therefore is included in prepaid expenses and other current assets on the balance sheets at December 31, 2010 and June 30, 2010.

(7) Debt

Short-term debt maturities and revolving line of credit Short-term debt at December 31, 2010 and June 30, 2010 reflects the current portion of the Company's industrial revenue bonds of approximately \$0.1 million.

The Company has \$20 million of maximum borrowing availability, subject to certain collateral restrictions, under a revolving line-of-credit facility provided in August 2009 by National City Business Credit, Inc. (now PNC Bank, National Association) to support working capital needs and other general corporate purposes. The new line-of-credit facility is secured by substantially all of the assets of the Company. Outstanding borrowings bear interest at a variable rate defined as the Bank's minimum base rate plus a specified margin, each component of which is determined separately for domestic and Eurodollar loans, but in no case less than a total rate of 7% per annum, which at December 31, 2010 was

7%. As a condition of the line-of-credit facility, the Company is subject to

Table of Contents

compliance with certain customary covenants, which the Company met at December 31, 2010. The Company had no borrowings drawn against the credit facility during the periods ended December 31, 2010 and June 30, 2010. The maturity date for the line-of-credit is August 14, 2012. The Company's prior line of credit was retired on August 14, 2009.

Long-term debt Long-term debt consists of the following at December 31, 2010 and June 30, 2010 (in thousands):

| | December 31, 2010 | June 30, 2010 |
|---|----------------------|------------------|
| Industrial revenue bonds, face value | \$ 1,964 | \$ 2,029 |
| Less unamortized purchase discount | (108) | (112) |
| Total long-term debt | 1,856 | 1,917 |
| Less: current portion | (121) | (121) |
| Long-term debt, net of current portion | \$ 1,735 | \$ 1,796 |

Industrial Revenue Bonds

In connection with its acquisition of Astro in May 2006, the Company assumed repayment of principal and interest on bonds originally issued on behalf of Astro by the State of Ohio. These bonds are Ohio State Economic Development Revenue Bonds, Series 2002-4. Astro originally entered into the loan agreement with the State of Ohio for the issuance of these bonds to finance the construction of Astro's current operating facility. The principal amount, including premium, was issued in 2002 and totaled approximately \$2.9 million. These bonds have interest rates which vary, dependent on the maturity date of the bonds ranging from 5.00% to 5.45%. Due to an increase in interest rates since the original issuance of the bonds, a discount amounting to approximately \$0.2 million on the date of assumption by Sparton was recorded.

The bonds carry certain sinking fund requirements generally obligating the Company to make monthly deposits of one twelfth of the annual obligation plus accrued interest. The purchase discount is being amortized ratably over the remaining term of the bonds. Amortization expense for each of the three months ended December 31, 2010 and 2009 was approximately \$3,000. Amortization expense for each of the six months ended December 31, 2010 and 2009 was approximately \$5,000. The Company also has an irrevocable letter of credit in the amount of approximately \$0.3 million, which is renewable annually, to secure repayment of a portion of the bonds.

Notes Payable Former Owners

Two notes payable with initial principal of \$3.75 million each, totaling \$7.5 million, were payable to the sellers of Astro, which is now operated under the Medical Device segment. These notes were repaid over four years, in aggregate semi-annual payments of principal and interest in the combined amount of approximately \$1.1 million on June 1 and December 1 of each year. Payments commenced on December 1, 2006. These notes each bore interest at 5.5% per annum. The notes were proportionately secured by the stock of Astro. On June 1, 2010, the Company made the final payments in satisfaction of these notes.

Bank Term Loan

The bank term loan, provided by National City Bank with an original principal of \$10.0 million, was being repaid over five years, with quarterly principal payments of \$0.5 million which commenced September 1, 2006. This loan bore interest at the variable rate of LIBOR plus 500 basis points, with interest calculated and paid quarterly along with the principal payment. The debt was secured by substantially all assets of the Company. On August 14, 2009, the Company paid off this term loan with a cash payment in connection with the replacement credit facility.

(8) Fair Value Measurements

As of December 31, 2010, the Company has no assets or liabilities which it measures and carries on its balance sheet at fair value on a recurring basis. The Company's long-term debt instruments, consisting of industrial revenue bonds at December 31, 2010, are carried at historical cost. As of December 31, 2010 and June 30, 2010, the fair value of the industrial revenue bonds was approximately \$2.2 million and \$2.3 million, respectively compared to carrying values of approximately \$1.9 million and \$1.9 million, respectively. These fair values were derived from discounted cash flow analyses based on the terms of the contracts and observable market data, including adjustment for non-performance risk.

Edgar Filing: SPARTON CORP - Form 10-Q

The fair value of accounts receivable and accounts payable approximated their carrying values at both December 31, 2010 and June 30, 2010.

Table of Contents**(9) Income Taxes**

The Company's effective income tax rate for the interim periods presented is based on management's estimate of the Company's effective tax rate for the applicable year and differs from the federal statutory income tax rate primarily due to applicable permanent differences, federal alternative minimum taxes, foreign income taxes, state income taxes and changes in the valuation allowance for deferred income taxes. In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible.

For the six months ended December 31, 2010 and 2009, provisions for income taxes of approximately \$0.2 million and \$0.2 million, respectively, were recognized relating to the increase in the deferred tax liability associated with the amortization of goodwill for tax purposes. There was no other federal income tax expense recorded for any of the three and six months ended December 31, 2010 or 2009, as income generated in these periods was offset by the utilization of previously recorded net operating loss carryforwards and the reversal of the related valuation allowance. The Company additionally recorded a benefit of approximately \$0.1 million during the six months ended December 31, 2010 relating to income tax carryback refunds from the Canadian government.

As a result of tax legislation enacted in November 2009, the Company elected during the three months ended December 31, 2009 to carry back a portion of its fiscal 2008 accumulated net operating loss to fiscal 2003, with this carryback generating a federal income tax refund of \$1.7 million. In addition, the Internal Revenue Service issued an industry directive providing guidance for extending the carryback period to ten years for losses related to environmental remediation. The Company elected during the three months ended December 31, 2009 to carryback its remediation losses from fiscal years 2006 through 2009, generating a federal income tax refund of \$0.6 million. As of December 31, 2010 and June 30, 2010, the Company has received \$2.0 million of the \$2.3 million in refund claims. In conjunction with these carryback tax filings, the Company released \$2.1 million of its deferred tax asset valuation allowance during the three months ended December 31, 2009.

At June 30, 2010, approximately \$15.7 million of U.S. income tax net operating loss carryovers were available to offset the Company's future Federal taxable income, of which \$4.7 million, \$5.1 million and \$5.9 million expire in 2029, 2028 and 2027, respectively. For state income tax purposes, the Company also had approximately \$11.5 million of net operating loss carryovers at June 30, 2010, of which \$0.6 million expire in 2011; \$1.5 million expire in 2012; \$0.9 million expire in 2013; \$0.5 million expire in 2014; \$3.3 million expire in 2027; \$3.1 million expire in 2028; and \$1.6 million expire in 2029. While management believes that realization of the deferred tax assets related to these net operating loss carryovers and other net temporary differences is possible, a total valuation allowance of \$10.9 million has been established as of June 30, 2010, against the \$11.7 million available for U.S. income tax purposes.

(10) Defined Benefit Pension Plan

Approximately 600 employees and retirees of the Company are covered by a defined benefit pension plan. Effective April 1, 2009, participation and the accrual of benefits in this pension plan were frozen, at which time all participants became fully vested. The components of net periodic pension expense are as follows for the three and six months ended December 31, 2010 and 2009 (in thousands):

| | For the Three Months Ended | | For the Six Months Ended | |
|---|----------------------------|-------------------|--------------------------|-------------------|
| | December 31, 2010 | December 31, 2009 | December 31, 2010 | December 31, 2009 |
| Service cost | \$ | \$ | \$ | \$ |
| Interest cost | 104 | 137 | 224 | 288 |
| Expected return on plan assets | (145) | (131) | (219) | (202) |
| Amortization of prior service cost | | | | |
| Amortization of unrecognized net actuarial loss | 38 | 83 | 117 | 187 |
| Net periodic benefit cost | (3) | 89 | 122 | 273 |
| Pro rata recognition of lump-sum settlements | 98 | 137 | 163 | 450 |
| Total periodic pension expense | \$ 95 | \$ 226 | \$ 285 | \$ 723 |

Table of Contents

Lump-sum settlement charges of approximately \$0.1 million and \$0.2 million were recognized during the three and six months ended December 31, 2010, respectively, in anticipation of lump-sum benefit distributions exceeding plan service and interest costs for the 2011 fiscal year. Lump-sum settlement charges of approximately \$0.1 million and \$0.5 million were recognized during the three and six months ended December 31, 2009. The Company's policy is to fund the plan based upon tax regulations and required legal funding requirements, as well as discretionary funding to ensure an adjusted funding target attainment percentage of at least 80%. During the three and six months ended December 31, 2010, approximately \$0.1 million and \$0.9 million, respectively, was contributed to the pension plan. During the three and six months ended December 31, 2009, approximately \$0.0 million and \$1.8 million, respectively, was contributed to the pension plan. For further information on future funding projections and other pension disclosures see Part II, Item 8, Note 8 Employee Retirement Benefit Plans of the Company's Annual Report on Form 10-K for the fiscal year ended June 30, 2010.

(11) Commitments and Contingencies

Environmental Remediation Sparton has been involved with ongoing environmental remediation since the early 1980's related to one of its former manufacturing facilities, located in Albuquerque, New Mexico (Coors Road). Although the Company entered into a long-term lease of the Coors Road property that was treated as a sale of property during the fourth quarter of fiscal 2010, it remains responsible for the remediation obligations related to its past operation of this facility. At December 31, 2010, Sparton had accrued approximately \$4.4 million as its best estimate of the remaining minimum future undiscounted financial liability with respect to this matter, of which approximately \$0.5 million is classified as a current liability and included on the balance sheet in other accrued expenses. The Company's minimum cost estimate is based upon existing technology and excludes legal and related consulting costs, which are expensed as incurred. The Company's estimate includes equipment and operating and maintenance costs for onsite and offsite pump and treat containment systems, as well as continued onsite and offsite monitoring. It also includes periodic reporting requirements.

On October 15, 2009, approximately \$3.1 million of cash was utilized to establish a trust, the Sparton Corporation Financial Assurance Trust, for remediation activity. The funds were held in Sparton's name and were invested with Sparton receiving the benefit of the investment return. As of June 30, 2010, approximately \$3.2 million was held in this trust. These funds were available for use against the expected remediation liability. The trust was established to meet the United States Environmental Protection Agency's (EPA) financial assurance requirements for the fiscal year ended June 30, 2010, with trust funds to be drawn upon only should Sparton not continue to meet its financial remediation requirements. The trust was to remain in place until the Company could again satisfy the EPA financial assurance requirements through compliance with financial ratios, as was previously attained on an annual basis until fiscal year 2009. Based on the Company's financial results for fiscal year 2010, the Company was again in compliance with the financial ratios and dissolved the trust during October 2010.

In fiscal 2003, Sparton reached an agreement with the United States Department of Energy (DOE) and others to recover certain remediation costs. Under the settlement terms, Sparton received cash and obtained some degree of risk protection as the DOE agreed to reimburse Sparton for 37.5% of certain future environmental expenses in excess of \$8.4 million incurred from the date of settlement, if any, of which approximately \$3.4 million has been incurred as of December 31, 2010 toward the \$8.4 million threshold. Uncertainties associated with environmental remediation contingencies are pervasive and often result in wide ranges of reasonably possible outcomes. Estimates developed in the early stages of remediation can vary significantly. Normally a finite estimate of cost does not become fixed and determinable at a specific point in time. Rather, the costs associated with environmental remediation become estimable over a continuum of events and activities that help to frame and define a liability. Factors which cause uncertainties for the Company include, but are not limited to, the effectiveness of the current work plans in achieving targeted results and proposals of regulatory agencies for desired methods and outcomes. It is possible that cash flows and results of operations could be materially affected by the impact of changes associated with the ultimate resolution of this contingency.

Customer Relationships The Company had an action before the U.S. Court of Federal Claims to recover damages arising out of an alleged infringement by the U.S. Navy of certain patents held by Sparton and used in the production of sonobuoys. Pursuant to an agreement between the Company and counsel conducting the litigation, a significant portion of the claim will be retained by the Company's counsel in contingent fees if the litigation is successfully concluded. A trial of the matter was conducted by the court in April 2008, with a decision against Sparton filed in August 2009 and published in September 2009. In October 2009, an appeal of this unfavorable decision was filed with the Federal Circuit Court of Appeals. Based on this decision, management believes that the Company's ability to obtain any recovery with respect to the claim is remote.

Table of Contents

Litigation On August 9, 2009, Sparton and certain subsidiaries were named as defendants in a wrongful death suit, alleging that a defective transmission shifter assembly in a 1996 Chrysler automobile caused a July 2007 death. The suit also named Chrysler LLC, Dura Automotive Systems, Inc., and Chandler Motors Company as defendants. The suit was filed in Pontotoc County Circuit Court in Mississippi. Sparton has not manufactured automotive shifter assemblies for Chrysler since December 1996, when it sold its KPI Group subsidiary to Dura Automotive Systems, Inc. The plaintiff seeks damages from the defendants for economic loss, pain and suffering, and loss of companionship, as well as punitive damages. Sparton has denied liability, has notified its insurance carriers regarding this claim, and is vigorously defending this matter. At this time, it is not possible to determine or predict the outcome of this suit, and as a result, no amounts have been accrued in the financial statements as of December 31, 2010. While no assurances can be given, the Company does not believe that this litigation, if adversely determined, would have a material adverse affect on the Company's financial position or results of operations.

Other In addition to the foregoing, from time to time, the Company is involved in various legal proceedings relating to claims arising in the ordinary course of business. The Company is not currently a party to any other such legal proceedings, the adverse outcome to which, individually or in the aggregate, is expected to have a material adverse effect on our business, financial condition or results of operations.

(12) Stock-Based Compensation

The Company has two long-term incentive plans. The Sparton Corporation Stock Incentive Plan, as amended and restated (the 2001 Plan) was approved by the Company's shareholders on October 24, 2001. The Sparton Corporation 2010 Long-Term Incentive Plan (the 2010 Plan) was approved by the Company's shareholders on October 28, 2009.

2001 Plan. Under the 2001 Plan, the Company may grant to employees and non-employee directors incentive or non-qualified stock options, stock appreciation rights, restricted stock and other stock-based awards. All of the stock options issued to date under the 2001 Plan have either three, five or ten-year lives with either immediate vesting or vesting on an annual basis over four years beginning one year after grant date. Restricted stock awards granted to date to employees under the 2001 Plan vest annually over periods ranging from approximately 2.5 to 3 years. Unrestricted stock awards granted to date under the 2001 Plan represent annual stock grants to directors as a component of their overall compensation. The 2001 Plan's termination date with respect to the granting of new awards is October 24, 2011. The total number of shares that may be granted under the 2001 Plan is 970,161 shares of the Company's common stock, of which amount, 46,245 shares remain available for awards as of December 31, 2010.

2010 Plan. Under the 2010 Plan, the Company may grant to employees, officers and directors of the Company or its subsidiaries incentive and non-qualified stock options, stock appreciation rights, restricted stock or restricted stock units, performance awards and other stock-based awards, including grants of shares. Restricted stock awards granted to date to employees under the 2010 Plan vest annually over four years, subject to achievement of certain financial performance metrics in addition to the service requirements. The 2010 Plan has a term of ten years. The total number of shares that may be awarded under the 2010 Plan is 1,000,000 shares of common stock, of which amount, 777,973 shares remain available for awards as of December 31, 2010.

The Company did not grant any stock options during the six months ended December 2010. During the three months ended December 31, 2009, the Company awarded an aggregate of 111,250 stock options to certain members of management at an exercise price of \$5.00. The stock options were immediately exercisable. The closing price of the Company's stock on the date of grant was \$4.59. The fair value of each grant is estimated at the grant date using the Black-Scholes option pricing method. The table below outlines the assumptions used for the options granted during the three months ended December 31, 2009:

| | Weighted Average |
|-------------------------|------------------|
| Risk free interest rate | 1.25% |
| Volatility | 78.10% |
| Dividend yield | 0.00% |
| Expected life in years | 3.00 |
| Fair value price | \$ 2.25 |

Table of Contents

The risk-free interest rate was determined using the then implied yield currently available for zero-coupon U.S. government issues with a remaining term equal to the expected life of the stock options. The expected volatility assumption used in the Black-Scholes option pricing models was based on the historical volatility of the Company's common stock. The Company does not currently intend to pay cash dividends and thus has assumed a 0% dividend yield. The Company estimates the expected life for stock options based on expected future exercise patterns.

The following table shows stock-based compensation expense by type of share-based award for the three and six months ended December 31, 2010 and 2009 included in the condensed consolidated statements of operations (in thousands):

| | For the Three Months Ended | | For the Six Months Ended | |
|---|----------------------------|-------------------|--------------------------|-------------------|
| | December 31, 2010 | December 31, 2009 | December 31, 2010 | December 31, 2009 |
| Fair value expense of stock option awards | \$ 249 | \$ 292 | \$ 372 | \$ 263 |
| Restricted stock | 249 | 92 | 372 | 121 |
| Total stock-based compensation | \$ 249 | \$ 384 | \$ 372 | \$ 384 |

The following table shows the total remaining unrecognized compensation cost related to restricted stock grants and the fair value expense of stock option awards, as well as the weighted average remaining required service period over which such costs will be recognized as of December 31, 2010:

| | Total Remaining Unrecognized Compensation Cost (in thousands) | Weighted Average Remaining Required Service Period (in years) |
|---|---|---|
| Fair value expense of stock option awards | \$ 803 | 2.33 |
| Restricted stock | 803 | 2.33 |
| | \$ 803 | 2.33 |

The following is a summary of options outstanding and exercisable at December 31, 2010:

| | Number of Shares | Weighted Average Exercise Price | Weighted Average Remaining Contractual Life (in years) | Aggregate Intrinsic Value (in thousands) |
|----------------------------------|------------------|---------------------------------|--|--|
| Outstanding at June 30, 2010 | 269,796 | \$ 6.89 | | |
| Granted | | | | |
| Exercised | | | | |
| Forfeited | (5,000) | 5.00 | | |
| Expired | | | | |
| Outstanding at December 31, 2010 | 264,796 | \$ 6.93 | 3.27 | \$ 392 |
| Exercisable at December 31, 2010 | 264,796 | \$ 6.93 | 3.27 | \$ 392 |

The following is a summary of activity for the six months ended December 31, 2010 related to shares granted under the Company's long-term incentive plans:

Edgar Filing: SPARTON CORP - Form 10-Q

| | Shares | Weighted Average Grant Date Fair Value |
|--|---------------|---|
| Restricted shares at June 30, 2010 | 262,095 | \$ 4.55 |
| Granted | 15,950 | 7.84 |
| Vested | (15,950) | 7.84 |
| Forfeited | | |
| Restricted shares at December 31, 2010 | 262,095 | \$ 4.55 |

Table of Contents**(13) Earnings Per Share Data**

Basic earnings per share is based on the weighted average number of common shares and participating securities outstanding during the period. Diluted earnings per share include the dilutive effect of additional potential common shares issuable under our stock-based compensation plan and are determined using the treasury stock method. Unvested restricted stock awards, which contain non-forfeitable rights to dividends whether paid or unpaid, are included in the number of shares outstanding for both basic and diluted earnings per share calculations. In the event of a net loss, unvested restricted stock awards are excluded from the calculation of both basic and diluted loss per share.

Earnings per share calculations, including weighted average number of shares of common stock outstanding used in calculating basic and diluted net income per share, for the three and six months ended December 31, 2010 and 2009 are as follows:

| | For the Three Months Ended | | For the Six Months Ended | |
|---|----------------------------|-------------------|--------------------------|-------------------|
| | December 31, 2010 | December 31, 2009 | December 31, 2010 | December 31, 2009 |
| Net income (in thousands) | \$ 1,435 | \$ 3,248 | \$ 5,515 | \$ 4,653 |
| Weighted average shares outstanding Basic | 10,209,376 | 9,964,420 | 10,204,955 | 9,957,964 |
| Net effect of dilutive stock options | 40,217 | | 24,494 | |
| Weighted average shares outstanding Diluted | 10,249,593 | 9,964,420 | 10,229,449 | 9,957,964 |
| Net income per share: | | | | |
| Basic | \$ 0.14 | \$ 0.33 | \$ 0.54 | \$ 0.47 |
| Diluted | \$ 0.14 | \$ 0.33 | \$ 0.54 | \$ 0.47 |

For each of the three and six months ended December 31, 2010, 262,095 unvested restricted shares were included in determining both basic and diluted earnings per share. For each of the three and six months ended December 31, 2009, 89,934 unvested restricted shares were included in determining both basic and diluted earnings per share. Potential shares of common stock excluded from diluted income per share computations because their inclusion would be anti-dilutive were 131,801 and 158,546 for the three and six months ended December 31, 2010, respectively, and were 278,135 for each of the three and six months ended December 31, 2009. For the three and six months ended December 31, 2009, basic and diluted loss per share are the same because the inclusion of the incremental potential shares of common stock from any assumed exercise of stock options is anti-dilutive.

(14) Comprehensive Income

Comprehensive income, which includes all changes in the Company's equity during the period except transactions with shareholders, consisted of the following for the three and six months ended December 31, 2010 and 2009 (in thousands):

| | For the Three Months Ended | | For the Six Months Ended | |
|---|----------------------------|-------------------|--------------------------|-------------------|
| | December 31, 2010 | December 31, 2009 | December 31, 2010 | December 31, 2009 |
| Net income | \$ 1,435 | \$ 3,248 | \$ 5,515 | \$ 4,653 |
| Other comprehensive income Change in unrecognized pension costs, net of tax | 136 | 637 | 280 | 637 |
| Comprehensive income | \$ 1,571 | \$ 3,885 | \$ 5,795 | \$ 5,290 |

Table of Contents**(15) Restructuring Activities****2009 Restructuring Plan**

During fiscal 2009, management initiated a full evaluation of the Company's operations and long-term business strategy. As a result, in the third quarter of fiscal 2009, management began to implement a formal turnaround plan focused on returning Sparton to profitability and the assurance of the Company's viability (the 2009 Restructuring Plan). These measures were designed to reduce operating costs, increase efficiencies, and improve our competitive position in response to excess capacity, the prevailing economy and the need to optimize manufacturing resources. These restructuring activities included, among other actions, plant consolidations, closures and sales, workforce reductions, customer contract disengagements, changes in employee pension and health care benefits and relocation of the Company's corporate office. Restructuring/impairment charges of approximately \$11.1 million have been incurred as of December 31, 2010 related to these activities of which approximately \$0.0 million, \$7.0 million and \$0.1 million were related to the Medical, EMS and DSS segments, respectively. The Company does not expect to recognize any additional costs related to these activities. Expected remaining cash expenditures related to the 2009 Restructuring Plan of approximately \$0.2 million primarily represent future lease payments and are expected to be paid out by the end of fiscal year 2012.

Delphi Medical Contract Manufacturing Business Acquisition Related Restructuring

During the first quarter of fiscal 2011, the Company took certain cost reduction actions in relation to its acquisition of certain assets related to the contract manufacturing business of Delphi Medical (the 2011 Colorado Restructuring Plan). These actions included a workforce reduction at the Colorado location and the consolidation of the Colorado manufacturing facilities from two to one. Restructuring/impairment charges recognized within the Medical segment of approximately \$0.1 million have been incurred as of December 31, 2010 related to these acquisition related restructuring activities. The Company does not expect to recognize any additional costs related to these activities. All cash expenditures related to the 2011 Colorado Restructuring Plan have been made as of December 31, 2010.

Summary of Restructuring Charges

The table below summarizes the nature and amount of restructuring actions for the year ended June 30, 2010 and the six months ended December 31, 2010 (in thousands):

| | Workforce Reduction (principally severance and retention bonuses) | Facility Closing | Lease Termination | Production Transfer | Total |
|--------------------------------------|--|-----------------------------|------------------------------|--------------------------------|--------------|
| Accrual balance at June 30, 2009 | \$ 375 | \$ 1,990 | \$ 1,990 | \$ 2,365 | \$ 2,365 |
| Restructuring charges | 350 | 1,188 | 409 | | 1,947 |
| Less: cash payments | (718) | (1,175) | (2,186) | | (4,079) |
| Restructuring reversals | | | | | |
| Accrual balance at June 30, 2010 | \$ 7 | \$ 13 | \$ 213 | \$ 233 | \$ 233 |
| Restructuring charges | 64 | 13 | | | 77 |
| Less: cash payments | (71) | (26) | (43) | | (140) |
| Restructuring reversals | | | | | |
| Accrual balance at December 31, 2010 | \$ | \$ | \$ 170 | \$ 170 | \$ 170 |

During the year ended June 30, 2010, approximately \$1.4 million of impairment related to property, plant and equipment was recorded. Additionally during fiscal year 2010, the Company sold its Jackson, Michigan and London, Ontario, Canada properties for an aggregate loss of approximately \$0.8 million. These impairments and loss on sales related to facility closings and were reflected in restructuring/impairment charges for the year ended June 30, 2010.

Edgar Filing: SPARTON CORP - Form 10-Q

Given the significance of, and the timing of the execution of such activities, accounting for the expected cost of these actions can involve periodic reassessments of estimates made at the time the original decisions were made. We continually evaluate the adequacy of the remaining liabilities under our restructuring initiatives. Although we believe that these estimates accurately reflect the costs of our restructuring plans, actual results may differ, thereby requiring us to periodically record additional provisions or reverse a portion of such provisions.

Table of Contents**(16) Business Segments**

Reportable segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, or group, in assessing performance and allocating resources. The Company operates predominantly in three markets – Medical Device, Electronic Manufacturing Services and Defense & Security Systems.

The Company uses an internal management reporting system, which provides important financial data to evaluate performance and allocate the Company's resources on a segment basis. Net sales are attributed to the segment in which the product is manufactured or service is performed. A segment's performance is evaluated based upon its operating income (loss). A segment's operating income (loss) includes its gross profit on sales less its selling and administrative expenses, including allocations of certain corporate operating expenses, but excludes some corporate and other unallocated items such as, interest expense, interest income, other income (expense) and income tax expense (benefit). Allocations of certain corporate operating expenses are allocated based on the nature of the service provided. Corporate and other unallocated costs primarily represent corporate administrative expenses related to those administrative, financial and human resource activities which are not allocated to operations and excluded from segment profit. These costs are not allocated to the segments, as management excludes such costs when assessing the performance of the segments. Inter-segment transactions are generally accounted for at amounts that approximate arm's length transactions. Identifiable assets by segments are those assets that are used in each segment's operations. The accounting policies for each of the segments are the same as for the Company taken as a whole.

Medical Device (Medical) operations are comprised of contract development, design, production and distribution of complex and sophisticated medical related electromechanical devices for customers with specialized needs, specifically in the design and manufacturing process, to assure product reliability and safety in accordance with Food and Drug Administration (FDA) guidelines and approvals. This group specializes in systems and procedures targeted to the requirements of medical Original Equipment Manufacturers (OEM) and Emerging Technology (ET) customers primarily in the In Vitro Diagnostic and Therapeutic Device segments of the Medical Device market space.

Electronic Manufacturing Services (EMS) operations are comprised of contract manufacturing, assembly, design, preproduction, prototyping and/or box build assembly for customers supporting the industrial, security sensing, medical, aerospace, defense, energy and telecommunications markets. These assemblies include flight control systems, fuel control systems for aerospace, medical diagnostics systems, security systems, detection systems, lighting and defense. Assemblies provided to this group's customers are state-of-the-art electronics, complex and legacy products (circuit card assemblies) and/or electromechanical assemblies in support of their products. EMS provides to its customers support services that include engineering services, design, material management, obsolescence analysis and management, documentation development, and process improvement. The segment strives to exceed customer's expectations of low cost and delivery performance. The common elements generally shared by EMS customers that produce the aforementioned products is the expectation of compliance to market quality certifications coupled with component cost reduction and continuous process improvements.

Defense & Security Systems (DSS) operations are comprised of design, development and production of products for a number of technologically significant programs aimed at fulfilling defense and commercial needs. Specializing in the development and production of complex electromechanical equipment, Sparton designs and manufactures sonobuoys, an anti-submarine warfare (ASW) device used by the U.S. Navy and foreign governments. This business unit also performs an engineering development function for the United States military and prime defense contractors on advanced technologies targeted as future defense products as well as replacement of current systems. The sonobuoy product line is built to the customer's demanding specifications. These products are restricted by International Tariff and Arms Regulations (ITAR), which limits opportunities for competition.

Table of Contents

Operating results and certain other financial information about the Company's three reportable segments for the three and six months ended December 31, 2010 and 2009 and as of December 31, 2010 and June 30, 2010 were as follows (in thousands):

| | For the Three Months Ended December 31, 2010 | | | | | |
|-------------------------------------|--|-----------|-----------|----------------------|--------------|-----------|
| | Medical | EMS | DSS | Other Unallocated | Eliminations | Total |
| Sales | \$ 25,650 | \$ 10,512 | \$ 13,179 | \$ | \$ (3,010) | \$ 46,331 |
| Gross profit | \$ 3,790 | \$ 749 | \$ 3,008 | \$ | \$ | \$ 7,547 |
| Operating income (loss) | \$ 1,850 | \$ (106) | \$ 2,069 | \$ (2,232) | \$ | \$ 1,581 |
| Selling and administrative expenses | \$ 1,830 | \$ 855 | \$ 784 | \$ 2,220 | \$ | \$ 5,689 |
| Depreciation/amortization | \$ 178 | \$ 120 | \$ 48 | \$ 18 | \$ | \$ 364 |
| Capital expenditures | \$ | \$ 598 | \$ 224 | \$ 64 | \$ | \$ 886 |

| | For the Three Months Ended December 31, 2009 | | | | | |
|-------------------------------------|--|-----------|-----------|----------------------|--------------|-----------|
| | Medical | EMS | DSS | Other Unallocated | Eliminations | Total |
| Sales | \$ 17,358 | \$ 14,324 | \$ 19,022 | \$ | \$ (3,481) | \$ 47,223 |
| Gross profit | \$ 2,463 | \$ 711 | \$ 4,961 | \$ | \$ | \$ 8,135 |
| Operating income (loss) | \$ 1,542 | \$ (470) | \$ 4,150 | \$ (3,743) | \$ | \$ 1,479 |
| Selling and administrative expenses | \$ 804 | \$ 827 | \$ 811 | \$ 2,667 | \$ | \$ 5,109 |
| Restructuring/impairment charges | \$ | \$ 354 | \$ | \$ 653 | \$ | \$ 1,007 |
| Depreciation/amortization | \$ 153 | \$ 114 | \$ 41 | \$ 3 | \$ | \$ 311 |
| Capital expenditures | \$ 94 | \$ 475 | \$ 66 | \$ 20 | \$ | \$ 655 |

| | For the Six Months Ended December 31, 2010 | | | | | |
|---|--|-----------|-----------|----------------------|--------------|------------|
| | Medical | EMS | DSS | Other Unallocated | Eliminations | Total |
| Sales | \$ 44,695 | \$ 22,840 | \$ 30,776 | \$ | \$ (6,213) | \$ 92,098 |
| Gross profit | \$ 5,657 | \$ 1,656 | \$ 7,260 | \$ | \$ | \$ 14,573 |
| Operating income (loss) | \$ 4,647 | \$ (9) | \$ 5,391 | \$ (4,344) | \$ | \$ 5,685 |
| Selling and administrative expenses | \$ 3,113 | \$ 1,683 | \$ 1,587 | \$ 4,140 | \$ | \$ 10,523 |
| Restructuring/impairment charges | \$ 77 | \$ | \$ | \$ | \$ | \$ 77 |
| Gain on sale of property, plant and equipment | \$ | \$ (18) | \$ | \$ | \$ | \$ (18) |
| Gain on acquisition | \$ (2,400) | \$ | \$ | \$ | \$ | \$ (2,400) |
| Depreciation/amortization | \$ 340 | \$ 227 | \$ 84 | \$ 36 | \$ | \$ 687 |
| Capital expenditures | \$ 2 | \$ 866 | \$ 402 | \$ 92 | \$ | \$ 1,362 |

| | For the Six Months Ended December 31, 2009 | | | | | |
|-------------------------------------|--|-----------|-----------|----------------------|--------------|-----------|
| | Medical | EMS | DSS | Other Unallocated | Eliminations | Total |
| Sales | \$ 36,914 | \$ 31,927 | \$ 32,367 | \$ | \$ (5,881) | \$ 95,327 |
| Gross profit | \$ 5,397 | \$ 1,729 | \$ 8,381 | \$ | \$ | \$ 15,507 |
| Operating income (loss) | \$ 3,406 | \$ (763) | \$ 7,077 | \$ (6,632) | \$ | \$ 3,088 |
| Selling and administrative expenses | \$ 1,757 | \$ 1,683 | \$ 1,304 | \$ 4,945 | \$ | \$ 9,689 |
| Restructuring/impairment charges | \$ | \$ 809 | \$ | \$ 1,074 | \$ | \$ 1,883 |
| Depreciation/amortization | \$ 306 | \$ 344 | \$ 82 | \$ 7 | \$ | \$ 739 |
| Capital expenditures | \$ 104 | \$ 477 | \$ 74 | \$ 32 | \$ | \$ 687 |

| | As of December 31, 2010 | | | | | |
|--------------|-------------------------|-----------|----------|----------------------|--------------|------------|
| | Medical | EMS | DSS | Other Unallocated | Eliminations | Total |
| Total assets | \$ 61,076 | \$ 23,007 | \$ 4,271 | \$ 38,268 | \$ | \$ 126,622 |

Table of Contents

| | As of June 30, 2010 | | | | | |
|--------------|---------------------|-----------|----------|----------------------|--------------|------------|
| | Medical | EMS | DSS | Other Unallocated | Eliminations | Total |
| Total assets | \$ 46,695 | \$ 25,219 | \$ 5,980 | \$ 41,967 | \$ | \$ 119,861 |

(17) New Accounting Standard

In July 2010, the Financial Accounting Standards Board (the FASB) issued Accounting Standards Update (ASU) No. 2010-20, Disclosures about the Credit Quality of Financing Receivables and the Allowance for Credit Losses, (ASU 2010-20). This update enhances the disclosure requirements about the credit quality and related allowance for credit losses of financing receivables. ASU 2010-20 was effective for Sparton in the second quarter of fiscal 2011. The adoption of this disclosure guidance did not have a significant impact on the Company's consolidated financial statements.

Table of Contents

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.

The following is management's discussion and analysis of certain significant events affecting Sparton Corporation (the Company or Sparton) results of operations and financial condition during the periods included in the accompanying financial statements. Additional information regarding the Company can be accessed via Sparton's website at www.sparton.com. Information provided at the website includes, among other items, the Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Quarterly Earnings Releases, News Releases, and the Code of Business Conduct and Ethics, as well as various corporate charters and documents.

The Private Securities Litigation Reform Act of 1995 reflects Congress' determination that the disclosure of forward-looking information is desirable for investors and encourages such disclosure by providing a safe harbor for forward-looking statements by corporate management. This report on Form 10-Q contains forward-looking statements within the scope of the Securities Act of 1933 and the Securities Exchange Act of 1934. The words expects, anticipates, believes, intends, plans, will, shall, and similar expressions, and the negatives of such expressions, are intended to identify forward-looking statements. In addition, any statements which refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements. The Company undertakes no obligation to publicly disclose any revisions to these forward-looking statements to reflect events or circumstances occurring subsequent to filing this Form 10-Q with the Securities and Exchange Commission (SEC). These forward-looking statements are subject to risks and uncertainties, including, without limitation, those discussed below and those described in Part I, Item 1A. Risk Factors in our Annual Report on Form 10-K for the year ended June 30, 2010. Accordingly, Sparton's future results may differ materially from historical results or from those discussed or implied by these forward-looking statements. The Company notes that a variety of factors could cause the actual results and experience to differ materially from anticipated results or other expectations expressed in the Company's forward-looking statements.

Business Overview

General

Sparton is a provider of complex and sophisticated electromechanical devices with capabilities that include concept development, industrial design, design and manufacturing engineering, production, distribution, and field service. The Company operates predominantly in three markets: Medical Device (Medical), Electronic Manufacturing Services (EMS) and Defense & Security Systems (DSS).

All of the Company's facilities are registered to ISO standards, including 9001 or 13485, with most having additional certifications. The Company's products and services include products for Original Equipment Manufacturers (OEM) and Emerging Technology (ET) customers that are microprocessor-based systems that include transducers, printed circuit boards and assemblies, sensors, and electromechanical components, as well as development and design engineering services relating to these product sales. Sparton also develops and manufactures sonobuoys, an anti-submarine warfare (ASW) device, used by the United States Navy and other free-world countries. Many of the physical and technical attributes in the production of sonobuoys are similar to those required in the production of the Company's other electrical and electromechanical products and assemblies.

The Company uses an internal management reporting system, which provides important financial data to evaluate performance and allocate the Company's resources on a market segment basis. Net sales for segments are attributed to the segment in which the product is manufactured or service is performed. A segment's performance is evaluated based upon its operating income (loss). A segment's operating income (loss) includes its gross profit on sales less its selling and administrative expenses, but excludes some corporate and other unallocated items such as, interest expense, interest income, other income (expense) and income tax expense (benefit). Corporate and other unallocated costs primarily represent corporate administrative expenses related to those administrative, financial and human resource activities which are not allocated to operations and excluded from segment profit. These costs are not allocated to the segments, as management excludes such costs when assessing the performance of the segments. Inter-segment transactions are generally accounted for at amounts that approximate arm's length transactions. The accounting policies for each of the segments are the same as for the Company taken as a whole.

Table of Contents

Medical Segment

Medical operations are comprised of contract development, design, production and distribution of complex and sophisticated medical related electromechanical devices for customers with specialized needs, specifically in the design and manufacturing process, to assure product reliability and safety in accordance with Food and Drug Administration (FDA) guidelines and approvals. This group specializes in systems and procedures targeted to the requirements of medical OEM and ET customers primarily in the In Vitro Diagnostic and Therapeutic Device segments of the Medical Device market space.

EMS Segment

EMS operations are comprised of contract manufacturing, assembly, design, preproduction, prototyping and/or box build assembly for customers supporting the industrial, security sensing, medical, aerospace, defense, energy and telecommunications markets. These assemblies include flight control systems, fuel control systems for aerospace, medical diagnostics systems, security systems, detection systems, lighting and defense. Assemblies provided to this group's customers are state-of-the-art electronics, complex and legacy products (circuit card assemblies) and/or electromechanical assemblies in support of their products. EMS provides to its customers support services that include engineering services, design, material management, obsolescence analysis and management, documentation development, and process improvement. The segment strives to exceed customer's expectations of low cost and delivery performance. The common elements generally shared by EMS customers that produce the aforementioned products is the expectation of compliance to market quality certifications coupled with component cost reduction and continuous process improvements.

DSS Segment

DSS operations are comprised of design, development and production of products for a number of technologically significant programs aimed at fulfilling defense and commercial needs. Specializing in the development and production of complex electromechanical equipment, Sparton designs and manufactures sonobuoys, an ASW device used by the U.S. Navy and foreign governments. This business unit also performs an engineering development function for the United States military and prime defense contractors on advanced technologies targeted as future defense products as well as replacement of current systems. The sonobuoy product line is built to the customer's demanding specifications. These products are restricted by International Tariff and Arms Regulations (ITAR), which limits opportunities for competition.

Risks and Uncertainties

Sparton, as a high-mix, low to medium volume supplier, provides rapid product turnaround for customers. High-mix describes customers needing multiple product types with generally low to medium volume manufacturing runs. As a contract manufacturer with customers in a variety of markets, the Company has substantially less visibility of end user demand and, therefore, forecasting sales can be problematic. Customers may cancel their orders, change production quantities and/or reschedule production for a number of reasons. Depressed economic conditions may result in customers delaying delivery of product, or the placement of purchase orders for lower volumes than previously anticipated. Unplanned cancellations, reductions, or delays by customers may negatively impact the Company's results of operations. As many of the Company's costs and operating expenses are relatively fixed within given ranges of production, a reduction in customer demand can disproportionately affect the Company's gross margins and operating income. The majority of the Company's sales have historically come from a limited number of customers. Significant reductions in sales to, or a loss of, one of these customers could materially impact our operating results if the Company were not able to replace those sales with new business.

Table of Contents

Other risks and uncertainties that may affect our operations, performance, growth forecasts and business results include, but are not limited to, timing and fluctuations in U.S. and/or world economies, sharp volatility of world financial markets over a short period of time, competition in the overall contract manufacturing business, availability of production labor and management services under terms acceptable to the Company, Congressional budget outlays for sonobuoy development and production, Congressional legislation, foreign currency exchange rate risk, uncertainties associated with the outcome of litigation, changes in the interpretation of environmental laws and the uncertainties of environmental remediation, customer labor and work strikes, and uncertainties related to defects discovered in certain of the Company's aerospace circuit boards. Further risk factors are the availability and cost of materials, as well as non-cancelable purchase orders we have committed to in relation to customer forecasts that can be subject to change. A number of events can impact these risks and uncertainties, including potential escalating utility and other related costs due to natural disasters, as well as political uncertainties such as the conflicts in Iraq and Afghanistan. The Company has encountered availability and extended lead time issues on some electronic components due to strong market demand; this resulted in higher prices and/or late deliveries. In addition, some electronics components used in production are available from a limited number of suppliers, or a single supplier, which may affect availability and/or pricing. Additionally, the timing of sonobuoy sales to the U.S. Navy is dependent upon access to the test range and successful passage of product tests performed by the U.S. Navy. Access to the Navy test range has been difficult to predict in the past. Additional risk factors that have arisen more recently include dependence on key personnel, recent volatility in the stock markets and the impact on the Company's pension plan. Finally, the Sarbanes-Oxley Act of 2002, and more recently the Frank-Dodd Act have required or will require changes in, and formalization of, some of the Company's corporate governance and compliance practices. The SEC and the New York Stock Exchange also passed rules and regulations requiring additional compliance activities. Compliance with these rules has increased administrative costs and may increase these costs further in the future. A further discussion of the Company's risk factors has been included in Part I, Item 1(a), Risk Factors, of the Company's Annual Report on Form 10-K for the fiscal year ended June 30, 2010. Management cautions readers not to place undue reliance on forward-looking statements, which are subject to influence by the enumerated risk factors as well as unanticipated future events.

Acquisition of Delphi Medical

On August 6, 2010, the Company completed the acquisition of certain assets related to the contract manufacturing business of Delphi Medical Systems, LLC (Delphi Medical or Delphi). The purchase price was approximately \$8.6 million, including additional consideration paid during the three months ended December 31, 2010 related to determination of the final inventory value. Total cash consideration paid of approximately \$8.4 million, including a \$2.0 million escrowed holdback, was net of approximately \$0.2 million for the assumption of retained employee accruals and was financed entirely through the use of Company cash. The purchase agreement provides for the recovery from Delphi Medical of an amount up to \$2.0 million, deposited in escrow at closing, for certain excess and obsolete inventory remaining on-hand at the end of the 18 month period from closing. These escrowed funds are additionally available for payment of potential seller indemnification obligations in relation to the agreement.

The acquired business, also now referred to as SMS Colorado, which is reported in the Company's Medical segment, is expected to add \$32 million in projected annual revenue from a new and diversified customer base and provides Sparton with a geographic presence in the western United States. Delphi Medical primarily manufactures OEM medical devices including blood separation equipment, spinal surgery products and 3-D eye mapping devices. It also provides engineering and manufacturing support to a market-leading environmental sensor company whose markets include meteorology, weather critical operations and controlled environment applications.

Sparton has determined that the fair value of the assets acquired and liabilities assumed related to this acquisition exceed the total purchase consideration and as a result the Company has recorded a gain on acquisition of \$2.4 million in the three months ended September 30, 2010. Sparton believes it was able to purchase this contract manufacturing business from Delphi Medical significantly below its fair value due to Delphi's desire to liquidate this asset in a timely manner and focus on its core business.

Included in the Company's Condensed Consolidated Statements of Operations for the three and six months ended December 31, 2010 are net sales of approximately \$11.4 million and \$17.3 million, respectively, and income before provision for income taxes of approximately \$1.2 million and \$3.6 million, respectively, resulting from the acquisition of Delphi Medical since August 6, 2010.

Table of Contents

The following table summarizes, on a pro forma basis, the results of operations of the acquired contract manufacturing business of Delphi Medical as though the acquisition had occurred as of July 1, 2009. The pro forma amounts presented are not necessarily indicative of either the actual consolidated results had the acquisition occurred as of July 1, 2009 or of future consolidated operating results (in thousands):

| | For the Three Months Ended December 31, | | | For the Six Months Ended December 31, | | |
|---|--|-----------------------|--------------------|---------------------------------------|-----------------------|-----------------------|
| | 2010 | | 2009 | 2010 | | 2009 |
| | Post Acquisition | Colorado Pro Forma | Pre Acquisition | Post Acquisition | Colorado Pro Forma | Colorado Pro Forma |
| Net sales | \$ 11,356 | \$ 6,990 | \$ 3,451 | \$ 17,296 | \$ 20,747 | \$ 16,548 |
| Gross profit | \$ 1,765 | \$ (99) | \$ 85 | \$ 2,322 | \$ 2,407 | \$ |
| Gain on acquisition | \$ | \$ | \$ | \$ (2,400) | \$ (2,400) | \$ |
| Operating income (loss) | \$ 1,110 | \$ (430) | \$ (85) | \$ 3,491 | \$ 3,406 | \$ (929) |
| Income before provision for (benefit from) income taxes | \$ 1,204 | \$ (44) | \$ (77) | \$ 3,623 | \$ 3,546 | \$ (518) |
| Net income (loss) | \$ 1,204 | \$ (44) | \$ (77) | \$ 3,623 | \$ 3,546 | \$ (518) |

The Company incurred legal, professional and other costs related to this acquisition aggregating approximately \$0.2 million. These costs were recognized as selling and administrative expenses of approximately \$0.1 million and \$0.1 million in the three months ended September 30, 2010 and June 30, 2010, respectively.

On August 6, 2010 and concurrent with the acquisition of Delphi Medical, the Company entered into leases for two facilities housing the operations of this contract manufacturing business. During the six months ended December 31, 2010, the Company initiated and completed the consolidation of the operations into one facility, and terminated the lease for the building which the Company exited.

Consolidated Results of Operations

The following discussion should be read in conjunction with the Unaudited Condensed Consolidated Financial Statements and Notes thereto included in Item 1 of this report.

Summary

The major elements affecting net income for the three and six months ended December 31, 2010 as compared to the three and six months ended December 31, 2009 were as follows (in millions):

| | For the Three Months Ended December 31, | For the Six Months Ended December 31, |
|--|---|---|
| Net income fiscal 2010 | \$ 3.2 | \$ 4.7 |
| Increased gross profit on Medical programs | \$ 1.3 | \$ 0.3 |
| Increased (decreased) gross profit on EMS programs | 0.0 | (0.1) |
| Decreased gross profit on DSS programs | (2.0) | (1.1) |
| Increased selling and administrative expenses | (0.6) | (0.8) |
| Increased internal research and development expenses | (0.2) | (0.3) |
| Decreased restructuring/impairment charges | 1.0 | 1.8 |
| Gain on acquisition | | 2.4 |
| Decreased carrying costs for closed facilities | 0.4 | 0.4 |
| Income taxes | (2.0) | (2.0) |
| Other | 0.3 | 0.2 |
| Net change | (1.8) | 0.8 |
| Net income fiscal 2011 | \$ 1.4 | \$ 5.5 |

Edgar Filing: SPARTON CORP - Form 10-Q

2nd quarter fiscal 2011 was comparatively impacted by:

Increased gross profit on Medical programs due to increased sales from the acquired Frederick, Colorado facility, partially offset by decreased sales from the Strongsville, Ohio facility.

Consistent gross profit on EMS programs due mainly to the positive effects of plant closures, consolidations and an aggressive continuous improvement program, offset by a decrease in sales volume.

Decreased gross profit on DSS programs due to decreased sales to foreign governments and the U.S. Navy, partially offset by increased digital compass sales.

Table of Contents

Increased selling and administrative expenses reflecting additional expenses related to the Company's Colorado facility, charges from an unfavorable arbitration award related to a dispute with a disengaged customer, increased internal research and development, business development expenses and information technology expenses, partially offset by reduced selling and administrative expenses due to the consolidation of EMS facilities during fiscal 2010 and decreased expenses related to the Company's long-term incentive plan.

No restructuring/impairment charges in the fiscal 2011 quarter compared to \$1.0 million in fiscal 2010.

Reduced closed facility carrying costs due to sales of properties.

Fiscal 2010 income tax benefit related to a change in income tax carryback regulations.
To date, fiscal 2011 was comparatively impacted by:

Increased gross profit on Medical programs due to increased sales from the acquired Frederick, Colorado facility, partially offset by decreased capacity utilization, unfavorable product mix and customer pricing adjustments at the Strongsville, Ohio facility.

Slightly decreased gross profit on EMS programs due mainly to a decrease in sales volume, partially offset by plant closures, consolidations and an aggressive continuous improvement program.

Decreased gross profit on DSS programs due to decreases in sonobuoy sales to foreign governments and in engineering sales revenue, partially offset by higher U.S. Navy sonobuoy production in the current year period and increased digital compass sales.

Increased selling and administrative expenses reflecting additional expenses related to the Company's Colorado facility, charges from an unfavorable arbitration award related to a dispute with a disengaged customer, increased internal research and development, business development expenses and information technology expenses, offset by reduced selling and administrative expenses due to the consolidation of EMS facilities during fiscal 2010.

Restructuring/impairment charges of approximately \$0.1 million in fiscal 2011 compared to \$1.9 million in fiscal 2010.

Fiscal 2011 gain on acquisition of certain assets related to the contract manufacturing business of Delphi Medical.

Reduced closed facility carrying costs due to sales of properties.

Fiscal 2010 income tax benefit related to a change in income tax carryback regulations.
Presented below are more detailed comparative data and discussions regarding our consolidated results of operations for the three and six months ended December 31, 2010 compared to the three and six months ended December 31, 2009. Results of operations for any period less than one year are not necessarily indicative of results of operations that may be expected for a full year.

For the Three Months Ended December 31, 2010 compared to the Three Months Ended December 31, 2009

The following table presents selected consolidated statement of operations data for the three months ended December 31, 2010 and 2009 (in thousands):

Edgar Filing: SPARTON CORP - Form 10-Q

| | 2010 | | 2009 | |
|--|-----------|------------|-----------|------------|
| | Total | % of Sales | Total | % of Sales |
| Net sales | \$ 46,331 | 100.0% | \$ 47,223 | 100.0% |
| Cost of goods sold | 38,784 | 83.7 | 39,088 | 82.8 |
| Gross profit | 7,547 | 16.3 | 8,135 | 17.2 |
| Selling and administrative expenses | 5,689 | 12.3 | 5,109 | 10.8 |
| Internal research and development expenses | 155 | 0.3 | | |
| Restructuring/impairment charges | | | 1,007 | 2.1 |
| Other operating expense, net | 122 | 0.3 | 540 | 1.2 |
| Operating income | 1,581 | 3.4 | 1,479 | 3.1 |
| Total other expense, net | (32) | (0.1) | (160) | (0.3) |
| Income before provision for income taxes | 1,549 | 3.3 | 1,319 | 2.8 |
| Provision for (benefit from) income taxes | 114 | 0.2 | (1,929) | (4.1) |
| Net income | \$ 1,435 | 3.1% | \$ 3,248 | 6.9% |

Table of Contents

The following table presents net sales for the three months ended December 31, 2010 and 2009 (in thousands):

| SEGMENT | 2010 | | 2009 | | % Change |
|--------------|-----------|------------|-----------|------------|----------|
| | Total | % of Total | Total | % of Total | |
| Medical | \$ 25,650 | 55% | \$ 17,358 | 37% | 48% |
| EMS | 10,512 | 23 | 14,324 | 30 | (27) |
| DSS | 13,179 | 28 | 19,022 | 40 | (31) |
| Eliminations | (3,010) | (6) | (3,481) | (7) | (14) |
| Totals | \$ 46,331 | 100% | \$ 47,223 | 100% | (2) |

The following table presents gross profit and gross profit as a percent of net sales for the three months ended December 31, 2010 and 2009 (in thousands):

| SEGMENT | 2010 | | 2009 | |
|---------|----------|-----|----------|-----|
| | Total | GP% | Total | GP% |
| Medical | \$ 3,790 | 15% | \$ 2,463 | 14% |
| EMS | 749 | 7 | 711 | 5 |
| DSS | 3,008 | 23 | 4,961 | 26 |
| Totals | \$ 7,547 | 16 | \$ 8,135 | 17 |

The following table presents operating income (loss) and operating income (loss) as a percent of net sales for the three months ended December 31, 2010 and 2009 (in thousands):

| SEGMENT | 2010 | | 2009 | |
|-------------------|----------|------------|----------|------------|
| | Total | % of Sales | Total | % of Sales |
| Medical | \$ 1,850 | 7% | \$ 1,542 | 9% |
| EMS | (106) | (1) | (470) | (3) |
| DSS | 2,069 | 16 | 4,150 | 22 |
| Other unallocated | (2,232) | | (3,743) | |
| Totals | \$ 1,581 | 3 | \$ 1,479 | 3 |

Medical

Medical sales in the three months ended December 31, 2010 included \$11.4 million of additional sales from the acquisition of certain assets related to the contract manufacturing business of Delphi Medical. Excluding these fiscal year 2011 incremental sales, Medical sales decreased approximately \$3.1 million in the three months ended December 31, 2010 as compared with the same quarter last year. This decrease in comparable sales was primarily due to decreased sales to two customers. Sales to one customer decreased by \$1.6 million, reflecting the suspension of production to make product enhancement modifications. This customer has notified the Company that the product enhancement modifications have been made, however, the Company cannot predict at what level sales for this product will resume. Sales to the second customer decreased by \$1.9 million as the customer continued to reduce inventory levels in the current year quarter related to one of its programs. Several other customers in the aggregate accounted for the remaining sales variance. Medical sales are dependent on a small number of key strategic customers. Siemens Diagnostics contributed 17% and 20% of consolidated company net sales during the three months ended December 31, 2010 and 2009, respectively. Medical backlog was approximately \$31.0 million at December 31, 2010. Commercial orders, in general, may be rescheduled or cancelled without significant penalty, and, as a result, may not be a meaningful measure of future sales. A majority of the December 31, 2010 Medical backlog is currently expected to be realized in the next 12 months.

Edgar Filing: SPARTON CORP - Form 10-Q

Gross profit varies from period to period and can be affected by a number of factors, including product mix, production efficiencies, capacity utilization, and costs associated with new program introduction. The gross profit percentage on Medical sales increased to 15% from 14% for the three months ended December 31, 2010 and 2009, respectively. This increase in margin on Medical sales reflects the Company's continued implementation of Lean Enterprise and its cost management efforts to mitigate decreased capacity utilization at the Company's Strongsville, Ohio facility. The quarter over quarter increase additionally reflects higher margins achieved at the Company's Frederick, Colorado facility. Gross profit percentage on sales from the acquired Delphi Medical business was 16% for the three months ended December 31, 2010.

Table of Contents

Selling and administrative expenses relating to the Medical segment were \$1.8 million and \$0.8 million for the three months ended December 31, 2010 and 2009, respectively. Reflected in the three months ended December 31, 2010 are increased direct and allocated expenses related to the recent Delphi Medical acquisition of \$0.7 million. Increased selling and administrative expenses from the Ohio facility reflected \$0.4 million in charges related to an unfavorable arbitration award related to a dispute with a disengaged customer. Increased business development efforts in the current fiscal quarter additionally contributed to the quarter over quarter increase. Offsetting these increases was a decrease in allocated corporate selling and administrative expenses to the Ohio facility in the current fiscal quarter.

EMS

EMS sales for the three months ended December 31, 2010 decreased approximately \$3.8 million as compared with the same quarter last year. This decrease primarily reflects decreased sales to two customers, whose combined decrease totaled approximately \$3.2 million from the prior year quarter. The decreases in sales to each of these customers reflect the quarter over quarter loss of certain programs with these customers and production delays due to customer engineering design changes. EMS sales include intercompany sales resulting primarily from the production of circuit boards that are then utilized in DSS product sales. Intercompany sales decreased approximately \$0.5 million in the comparable three month period. These intercompany sales are eliminated in consolidation. Several other customers in the aggregate accounted for the remaining sales variance. Goodrich contributed 9% and 13% of consolidated company net sales during the three months ended December 31, 2010 and 2009, respectively. EMS backlog was approximately \$25.0 million at December 31, 2010. Commercial orders, in general, may be rescheduled or cancelled without significant penalty, and, as a result, may not be a meaningful measure of future sales. A majority of the December 31, 2010 EMS backlog is currently expected to be realized in the next 12 months.

The gross profit percentage on EMS sales increased to 7% for the three months ended December 31, 2010 compared to 5% for the three months ended December 31, 2009. The quarter over quarter comparison reflects improved performance, consolidation of EMS operations and an aggressive continuous improvement program, partially offset by the impact of the overall decrease in sales volume. Additionally offsetting these improvements, margin was favorably impacted in the prior year quarter by price increases to Honeywell during its disengagement. Plant closures and restructuring activities are discussed further in Note 15 of the Unaudited Condensed Consolidated Financial Statements.

Selling and administrative expenses relating to the EMS segment were \$0.9 million for the three months ended December 31, 2010 compared to \$0.8 million for the three months ended December 31, 2009, as decreased expenses related to the consolidation of EMS facilities during fiscal 2010 were offset by increased business development efforts in the current fiscal quarter.

Restructuring/impairment charges relating to the EMS segment were \$0.4 million for the three months ended December 31, 2009. No restructuring/impairment charges relating to the EMS segment were recognized in the current year quarter. For a further discussion of the restructuring activity see Note 15 to the Unaudited Condensed Consolidated Financial Statements.

DSS

DSS sales for the three months ended December 31, 2010 decreased by \$5.8 million from the second quarter of last fiscal year, reflecting decreases in sonobuoy sales to foreign governments and in engineering sales revenue, as well as slightly lower U.S. Navy sonobuoy production in the current year quarter. Partially offsetting these decreases were increased digital compass sales. Total sales to the U.S. Navy in the three months ended December 31, 2010 and 2009 was approximately \$10.2 million and \$12.3 million, or 22% and 26%, respectively, of consolidated Company net sales for those periods. Sonobuoy sales to foreign governments were \$1.9 million and \$6.4 million in the three months ended December 31, 2010 and 2009, respectively. DSS backlog was approximately \$63.3 million at December 31, 2010. A majority of the December 31, 2010 DSS backlog is currently expected to be realized within the next 12 to 16 months.

Table of Contents

The gross profit percentage on DSS sales for the three months ended December 31, 2010 was 23% compared to 26% for the three months ended December 31, 2009. The Company continues to realize elevated margins on the production of U.S. Navy sonobuoys reflecting success in sustaining previous improvements in lot testing success through robust product failure analysis and corrective action processes and in production efficiency through the continued implementation of Lean Enterprise. Gross profit percentage was negatively impacted in the current year quarter by decreased overall sales, particularly decreased sales to foreign governments as compared to the prior year quarter.

Selling and administrative expenses relating to the DSS segment were \$0.8 million for each of the three months ended December 31, 2010 and 2009, respectively, reflecting increased direct selling and administrative expenses due to increased business development efforts in the current fiscal quarter, offset by a decrease in allocated corporate selling and administrative expenses.

Internal research and development expenses reflect costs incurred for the internal development of technologies for use in navigation, oil and gas exploration and port security. These costs include salaries and related expenses, contract labor and consulting costs, materials and the cost of certain research and development specific equipment. The Company incurred \$0.2 million of internally funded research and development expenses in the three months ended December 31, 2010. No internally funded research and development expense was recognized in the prior year period.

Other Unallocated

Total corporate selling and administrative expenses were \$3.8 million and \$4.4 million for the three months ended December 31, 2010 and 2009, respectively, reflecting decreased professional fees and decreased expenses related to the Company's long-term incentive plan. Of these costs, \$1.6 million and \$1.7 million, respectively, were allocated to segment operations in these periods. Allocations of corporate selling and administrative expenses are based on the nature of the service provided and can fluctuate from period to period.

Other operating expenses were \$0.0 million and \$0.4 million for the three months ended December 31, 2010 and 2009, respectively. These expenses primarily represent ongoing costs for closed facilities and facilities held for sale.

Non-segment related restructuring/impairment charges were \$0.7 million for the three months ended December 31, 2009 and were related to relocation of the Company's corporate office. No non-segment restructuring/impairment charges were recognized in the current year quarter. For a further discussion of the restructuring activity see Note 15 to the Unaudited Condensed Consolidated Financial Statements.

Interest expense consists of interest and fees on our outstanding debt and revolving credit facility (see Note 7 to the Unaudited Condensed Consolidated Financial Statements), including amortization of financing costs. Interest expense was \$0.2 million for each of the three months ended December 31, 2010 and 2009, respectively.

The Company is responsible for income taxes within each jurisdiction in which it operates. The Company recorded income tax expense of approximately \$0.1 million for the three months ended December 31, 2010 compared to an income tax benefit of approximately \$1.9 million for the three months ended December 31, 2009. The fiscal 2010 benefit reflects the release of \$2.1 million of deferred tax asset valuation allowance in relation to tax regulation changes related to carryback provisions. See Note 9 to the Unaudited Condensed Consolidated Financial Statements for a further discussion of income taxes.

Due to the factors described above, the Company reported net income of \$1.4 million (\$0.14 per share, basic and diluted) for the three months ended December 31, 2010, compared to net income of \$3.2 million (\$0.33 per share, basic and diluted) for the corresponding quarter last year.

Table of Contents**For the Six Months Ended December 31, 2010 compared to the Six Months Ended December 31, 2009**

The following table presents selected consolidated statement of operations data for the six months ended December 31, 2010 and 2009 (in thousands):

| | 2010 | | 2009 | |
|--|-----------|------------|-----------|------------|
| | Total | % of Sales | Total | % of Sales |
| Net sales | \$ 92,098 | 100.0% | \$ 95,327 | 100.0% |
| Cost of goods sold | 77,525 | 84.2 | 79,820 | 83.7 |
| Gross profit | 14,573 | 15.8 | 15,507 | 16.3 |
| Selling and administrative expenses | 10,523 | 11.4 | 9,689 | 10.2 |
| Internal research and development expenses | 282 | 0.3 | | |
| Restructuring/impairment charges | 77 | 0.1 | 1,883 | 2.0 |
| Gain on acquisition | (2,400) | (2.6) | | 0.0 |
| Other operating expense, net | 406 | 0.4 | 847 | 0.9 |
| Operating income | 5,685 | 6.2 | 3,088 | 3.2 |
| Total other expense, net | (70) | (0.1) | (330) | (0.3) |
| Income before provision for income taxes | 5,615 | 6.1 | 2,758 | 2.9 |
| Provision for (benefit from) income taxes | 100 | 0.1 | (1,895) | (2.0) |
| Net income | \$ 5,515 | 6.0% | \$ 4,653 | 4.9% |

The following table presents net sales for the six months ended December 31, 2010 and 2009 (in thousands):

| SEGMENT | 2010 | | 2009 | | % Change |
|--------------|-----------|------------|-----------|------------|----------|
| | Total | % of Total | Total | % of Total | |
| Medical | \$ 44,695 | 49% | \$ 36,914 | 39% | 21% |
| EMS | 22,840 | 25 | 31,927 | 33 | (28) |
| DSS | 30,776 | 33 | 32,367 | 34 | (5) |
| Eliminations | (6,213) | (7) | (5,881) | (6) | 6 |
| Totals | \$ 92,098 | 100% | \$ 95,327 | 100% | (3) |

The following table presents gross profit and gross profit as a percent of net sales for the six months ended December 31, 2010 and 2009 (in thousands):

| SEGMENT | 2010 | | 2009 | |
|---------|-----------|-----|-----------|-----|
| | Total | GP% | Total | GP% |
| Medical | \$ 5,657 | 13% | \$ 5,397 | 15% |
| EMS | 1,656 | 7 | 1,729 | 5 |
| DSS | 7,260 | 24 | 8,381 | 26 |
| Totals | \$ 14,573 | 16 | \$ 15,507 | 16 |

The following table presents operating income (loss) and operating income (loss) as a percent of net sales for the six months ended December 31, 2010 and 2009 (in thousands):

Edgar Filing: SPARTON CORP - Form 10-Q

| SEGMENT | 2010 | | 2009 | |
|-------------------|-----------------|------------|-----------------|------------|
| | Total | % of Sales | Total | % of Sales |
| Medical | \$ 4,647 | 10% | \$ 3,406 | 9% |
| EMS | (9) | | (763) | (2) |
| DSS | 5,391 | 18 | 7,077 | 22 |
| Other unallocated | (4,344) | | (6,632) | |
| Totals | \$ 5,685 | 6 | \$ 3,088 | 3 |

Table of Contents***Medical***

Medical sales in the six months ended December 31, 2010 included \$17.3 million of additional sales from the acquisition of certain assets related to the contract manufacturing business of Delphi Medical. Excluding these fiscal year 2011 incremental sales, Medical sales decreased approximately \$9.5 million in the six months ended December 31, 2010 as compared with the same period last year. This decrease in comparable sales was primarily due to decreased sales to three customers. Sales to one customer decreased by \$4.6 million, reflecting the suspension of production to make product enhancement modifications. This customer has notified the Company that the product enhancement modifications have been made, however, the Company cannot predict at what level sales for this product will resume. Sales to another customer decreased by \$4.3 million, reflecting the customer's inventory reduction efforts in the current year period, the end of life of one of its programs and technical issues on another. Sales to a third customer decreased by \$1.3 million, reflecting this customer's disengagement during fiscal 2011. Several other customers in the aggregate accounted for the remaining sales variance. Medical sales are dependent on a small number of key strategic customers. Siemens Diagnostics contributed 17% and 21% of consolidated company net sales during the six months ended December 31, 2010 and 2009, respectively.

The gross profit percentage on Medical sales decreased to 13% from 15% for the six months ended December 31, 2010 and 2009, respectively. This decline in margin on Medical sales reflects decreased capacity utilization at the Company's Strongsville, Ohio facility. Additionally contributing to the decrease in margin was unfavorable product mix between the two periods and the loss of certain favorable materials pricing benefits in the prior year to customer pricing adjustments. These downward pressures on gross margin were partially offset by greater operating efficiencies from consolidation of manufacturing operations and the Company's continued implementation of Lean Enterprise and its cost management efforts. Gross profit percentage on sales from the acquired Delphi Medical business was 13% for the period since acquisition.

Selling and administrative expenses relating to the Medical segment were \$3.1 million and \$1.8 million for the six months ended December 31, 2010 and 2009, respectively. Reflected in the six months ended December 31, 2010 are increased direct and allocated expenses related to the recent Delphi Medical acquisition of \$1.2 million. Increased selling and administrative expenses from the Ohio facility reflected \$0.4 million in charges related to an unfavorable arbitration award related to a dispute with a disengaged customer. Increased business development efforts in the current fiscal period additionally contributed to the period over period increase. Offsetting these increases was a decrease in allocated corporate selling and administrative expenses to the Ohio facility in the current fiscal period.

Restructuring/impairment charges relating to the Medical segment were \$0.1 million for the six months ended December 31, 2010 and related to the workforce reduction and facility consolidation at the Company's Colorado facility. No restructuring/impairment charges relating to the Medical segment were recognized in the prior year period. For a further discussion of the restructuring activity see Note 15 to the Unaudited Condensed Consolidated Financial Statements.

On August 6, 2010, the Company completed the acquisition of certain assets related to the contract manufacturing business of Delphi Medical. The Company determined that the fair value of the assets acquired and liabilities assumed related to this acquisition exceeded the total purchase consideration and as a result the Company recorded a gain on acquisition of \$2.4 million in six months ended December 31, 2010. For a further discussion of this acquisition, see Note 2 to the Unaudited Condensed Consolidated Financial Statements.

EMS

EMS sales for the six months ended December 31, 2010 decreased approximately \$9.1 million as compared with the same period last year. This decrease primarily reflects decreased sales to three customers, whose combined decrease totaled approximately \$10.2 million from the prior year period. Sparton disengaged with one of these customers, Honeywell, during the three months ended December 31, 2009. The decreases in sales to the remaining two customers reflect the period over period loss of certain programs with these customers and production delays due to customer engineering design changes. Partially offsetting these decreases, sales to another customer increased by approximately \$1.0 million. EMS sales include intercompany sales resulting primarily from the production of circuit boards that are then utilized in DSS product sales. Intercompany sales increased approximately \$0.3 million in the comparable six month period. These intercompany sales are eliminated in consolidation. Several other customers in the aggregate accounted for the remaining sales variance. One customer, Goodrich, contributed 10% and 12% of consolidated company net sales during the six months ended December 31, 2010 and 2009, respectively.

Table of Contents

The gross profit percentage on EMS sales increased to 7% for the six months ended December 31, 2010 compared to 5% for the six months ended December 31, 2009. The period over period comparison reflects improved performance, consolidation of EMS operations and an aggressive continuous improvement program, partially offset by the overall decrease in sales volume. Additionally offsetting these improvements, margin was favorably impacted in the prior year period by price increases to Honeywell during its disengagement. Plant closures and restructuring activities are discussed further in Note 15 of the Unaudited Condensed Consolidated Financial Statements.

Selling and administrative expenses relating to the EMS segment were \$1.7 million for each of the six months ended December 31, 2010 and 2009, respectively, as decreased expenses related to the consolidation of EMS facilities during fiscal 2010 were offset by increased business development efforts in the current fiscal quarter.

Restructuring/impairment charges relating to the EMS segment were \$0.8 million for the six months ended December 31, 2009. No restructuring/impairment charges relating to the EMS segment were recognized in the current year period. For a further discussion of the restructuring activity see Note 15 to the Unaudited Condensed Consolidated Financial Statements.

DSS

DSS sales for the six months ended December 31, 2010 decreased by \$1.6 million from the first six months of last fiscal year, reflecting decreases in sonobuoy sales to foreign governments and in engineering sales revenue. Partially offsetting these decreases was higher U.S. Navy sonobuoy production in the current year period and increased digital compass sales. Total sales to the U.S. Navy in the six months ended December 31, 2010 and 2009 was approximately \$25.6 million and \$22.6 million, or 28% and 24%, respectively, of consolidated Company net sales for those periods. Sonobuoy sales to foreign governments were \$3.6 million and \$8.8 million in the six months ended December 31, 2010 and 2009, respectively.

The gross profit percentage on DSS sales for the six months ended December 31, 2010 was 24% compared to 26% for the six months ended December 31, 2009. The Company continues to realize elevated margins on the production of U.S. Navy sonobuoys reflecting success in sustaining previous improvements in lot testing success through robust product failure analysis and corrective action processes and in production efficiency through the continued implementation of Lean Enterprise. Gross profit percentage was negatively impacted in the current year period by decreased overall sales, particularly decreased sales to foreign governments as compared to the prior year period.

Selling and administrative expenses relating to the DSS segment were \$1.6 million and \$1.3 million for the six months ended December 31, 2010 and 2009, respectively, reflecting increased direct selling and administrative expenses due to increased business development efforts in the current fiscal period and an increase in allocated corporate selling and administrative expenses.

Internal research and development expenses reflect costs incurred for the internal development of technologies for use in navigation, oil and gas exploration and port security. These costs include salaries and related expenses, contract labor and consulting costs, materials and the cost of certain research and development specific equipment. The Company incurred \$0.3 million of internally funded research and development expenses in the six months ended December 31, 2010. No internally funded research and development expense was recognized in the prior year period.

Other Unallocated

Total corporate selling and administrative expenses were \$7.5 million and \$7.9 million for the six months ended December 31, 2010 and 2009, respectively, reflecting decreased expenses related to the Company's long-term incentive plan and decreased professional fees, offset by increased information technology expenses. Of these costs, \$3.4 million and \$2.9 million, respectively, were allocated to segment operations in these periods. Allocations of corporate selling and administrative expenses are based on the nature of the service provided and can fluctuate from period to period.

Other operating expenses were \$0.2 million and \$0.6 million for the six months ended December 31, 2010 and 2009, respectively. These expenses primarily represent ongoing costs for closed facilities and facilities held for sale.

Non-segment related restructuring/impairment charges were \$1.1 million for the six months ended December 31, 2009 and were related to relocation of the Company's corporate office. No non-segment restructuring/impairment charges were recognized in the current year six month period. For a further discussion of the restructuring activity see Note 15 to the Unaudited Condensed Consolidated Financial Statements.

Table of Contents

Interest expense consists of interest and fees on our outstanding debt and revolving credit facility (see Note 7 to the Unaudited Condensed Consolidated Financial Statements), including amortization of financing costs. Interest expense was \$0.4 million for the six months ended December 31, 2010 compared to \$0.5 million for the six months ended December 31, 2009. The decrease primarily reflects the repayment of the Company's line-of-credit and bank term debt with available cash on August 14, 2009.

The Company is responsible for income taxes within each jurisdiction in which it operates. The Company recorded income tax expense of approximately \$0.1 million for the six months ended December 31, 2010 compared to an income tax benefit of approximately \$1.9 million for the six months ended December 31, 2009. The fiscal 2011 income tax expense includes a \$0.1 million benefit relating to income tax carryback refunds received from the Canadian government. The fiscal 2010 benefit reflects the release of \$2.1 million of deferred tax asset valuation allowance in relation to tax regulation changes related to carryback provisions. See Note 9 to the Unaudited Condensed Consolidated Financial Statements for a further discussion of income taxes.

Due to the factors described above, the Company reported net income of \$5.5 million (\$0.54 per share, basic and diluted) for the six months ended December 31, 2010, compared to net income of \$4.7 million (\$0.47 per share, basic and diluted) for the corresponding period last year.

Liquidity and Capital Resources

Certain of the Company's DSS contracts allow for billings to occur when certain milestones under the applicable program are reached, independent of the amount expended by Sparton as of such date. These advance billings reduce the amount of cash that would otherwise be required during the performance of these contracts. As of December 31, 2010 and June 30, 2010, \$22.8 million and \$21.6 million, respectively, of billings in excess of costs were received. The Company currently expects to meet its liquidity needs through a combination of sources including, but not limited to, operations, existing cash balances, its revolving line-of-credit, anticipated continuation of advance billings on certain DSS contracts, the potential proceeds from sale of our remaining closed facility, and continued improvement in inventory management. With the above sources providing the expected cash flows, the Company currently believes that it will have sufficient liquidity for our anticipated needs over the next 12 months, but no assurances regarding liquidity can be made.

Operating activities provided \$6.0 million and \$0.9 million of net cash flows in the six months ended December 31, 2010 and 2009, respectively. Excluding changes in working capital, operating activities provided \$4.8 million and \$4.9 million in the first half of fiscal 2011 and 2010, respectively, reflecting the Company's relative operating performance during those periods. Working capital provided \$1.2 million of net cash flows in the six months ended December 31, 2010 and used \$4.0 million in the six months ended December 31, 2009. Working capital related cash flows in the first six months of fiscal 2011 primarily reflect reduced working capital requirements related to lower sequential quarterly sales volumes and the Company's continued inventory management efforts, particularly in relation to the Colorado facility's acquired inventory. Additionally contributing to the positive working capital cash flows were the collection of advance billings related to U.S. Navy contracts during the six month period in excess of the funding of production under those contracts. Partially offsetting these sources was the initial working capital funding related to the Company's newly acquired Colorado facility as well as a funding of a pension contribution during the period. Working capital related cash flows in the first six months of fiscal 2010 primarily reflect the funding of production related to U.S. Navy contracts during the year in excess of advance billings received as well as cash outlays relating to restructuring activities and a pension contribution, offset by reduced working capital requirements related to lower sales volumes due to customer disengagements, the closing of facilities and the Company's inventory management efforts.

Cash flows used in investing activities in the six months ended December 31, 2010 and 2009 totaled \$6.6 million and \$4.3 million, respectively. The six months ended December 31, 2010 reflects the acquisition of certain assets related to the contract manufacturing business of Delphi Medical. The consideration paid of \$8.4 million is net of assumed employee accrual adjustments. The purchase was financed entirely through the use of Company cash. The six months ended December 31, 2009 reflects the payment of contingent purchase consideration to the prior owners of Astro Instrumentation, LLC. Fiscal 2010 reflects the utilization of \$3.1 million to establish a trust, the Sparton Corporation Financial Assurance Trust, related to environmental remediation activities at one of Sparton's former facilities. The funds were held in Sparton's name and were invested with Sparton receiving the benefit of the investment return. These funds were available for use to satisfy the expected remediation liability reflected in the June 30, 2010 balance sheet. Fiscal 2011 reflects the Company's dissolution of the trust during October 2010. For further discussion of this remediation activity, see Commitments and Contingencies below. Capital expenditures for the six months ended December 31, 2010 and 2009 were approximately \$1.4 million and \$0.7 million, respectively.

Table of Contents

Cash flows used in financing activities in the six months ended December 31, 2010 and 2009 totaled approximately \$0.1 million and \$20.8 million, respectively. The primary use of cash from financing activities in the first six months of fiscal 2010 was the repayment of debt. Fiscal 2010 also reflects the payment of financing fees related to the Company's new revolving credit facility. In the six months ended December 31, 2009, the Company paid off the existing balance on its line-of-credit facility totaling \$15.5 million, and the \$3.4 million remaining balance on its term loan, with National City Bank.

As of December 31, 2010, the Company's bank line-of-credit facility totaled \$20.0 million, subject to certain collateral restrictions, with no borrowings against the available funds. This bank debt is subject to certain customary covenants which were met at December 31, 2010. The maturity date for this line-of-credit is August 14, 2012. The Company also has approximately \$1.9 million of industrial revenue bonds outstanding at December 31, 2010. See Note 7, Debt, of the Notes to Condensed Consolidated Financial Statements in this Quarterly Report on Form 10-Q for a further discussion of the Company's debt.

Commitments and Contingencies

Environmental Remediation

Sparton has been involved with ongoing environmental remediation since the early 1980's related to one of its former manufacturing facilities, located in Albuquerque, New Mexico (Coors Road). Although the Company entered into a long-term lease of the Coors Road property that was treated as a sale of property during the fourth quarter of fiscal 2010, it remains responsible for the remediation obligations related to its past operation of this facility. At December 31, 2010, Sparton had accrued approximately \$4.4 million as its best estimate of the remaining minimum future undiscounted financial liability with respect to this matter, of which approximately \$0.5 million is classified as a current liability and included on the balance sheet in other accrued expenses. The Company's minimum cost estimate is based upon existing technology and excludes legal and related consulting costs, which are expensed as incurred. The Company's estimate includes equipment and operating and maintenance costs for onsite and offsite pump and treat containment systems, as well as continued onsite and offsite monitoring. It also includes periodic reporting requirements.

On October 15, 2009, approximately \$3.1 million of cash was utilized to establish a trust, the Sparton Corporation Financial Assurance Trust, for remediation activity. The funds were held in Sparton's name and were invested with Sparton receiving the benefit of the investment return. As of June 30, 2010, approximately \$3.2 million was held in this trust. These funds were available for use against the expected remediation liability. The trust was established to meet the United States Environmental Protection Agency's (EPA) financial assurance requirements for the fiscal year ended June 30, 2010, with trust funds to be drawn upon only should Sparton not continue to meet its financial remediation requirements. The trust was to remain in place until the Company could again satisfy the EPA financial assurance requirements through compliance with financial ratios, as was previously attained on an annual basis until fiscal year 2009. Based on the Company's financial results for fiscal year 2010, the Company was again in compliance with the financial ratios and dissolved the trust during October 2010.

In fiscal 2003, Sparton reached an agreement with the United States Department of Energy (DOE) and others to recover certain remediation costs. Under the settlement terms, Sparton received cash and obtained some degree of risk protection as the DOE agreed to reimburse Sparton for 37.5% of certain future environmental expenses in excess of \$8.4 million incurred from the date of settlement, if any, of which approximately \$3.4 million has been incurred as of December 31, 2010 toward the \$8.4 million threshold. Uncertainties associated with environmental remediation contingencies are pervasive and often result in wide ranges of reasonably possible outcomes. Estimates developed in the early stages of remediation can vary significantly. Normally a finite estimate of cost does not become fixed and determinable at a specific point in time. Rather, the costs associated with environmental remediation become estimable over a continuum of events and activities that help to frame and define a liability. Factors which cause uncertainties for the Company include, but are not limited to, the effectiveness of the current work plans in achieving targeted results and proposals of regulatory agencies for desired methods and outcomes. It is possible that cash flows and results of operations could be materially affected by the impact of changes associated with the ultimate resolution of this contingency.

The Company and its subsidiaries are also involved in certain existing compliance issues with the EPA and various state agencies, including being named as a potentially responsible party at several sites. Potentially responsible parties (PRPs) can be held jointly and severally liable for the clean-up costs at any specific site. The Company's past experience, however, has indicated that when it has contributed relatively small amounts of materials or waste to a specific site relative to other PRPs, its ultimate share of any clean-up costs has been minor. Based upon available information, the Company believes it has contributed only small amounts to those sites in which it is currently viewed as a PRP.

Table of Contents***Customer Relationships***

The Company had an action before the U.S. Court of Federal Claims to recover damages arising out of an alleged infringement by the U.S. Navy of certain patents held by Sparton and used in the production of sonobuoys. Pursuant to an agreement between the Company and counsel conducting the litigation, a significant portion of the claim will be retained by the Company's counsel in contingent fees if the litigation is successfully concluded. A trial of the matter was conducted by the court in April 2008, with a decision against Sparton filed in August 2009 and published in September 2009. In October 2009, an appeal of this unfavorable decision was filed with the Federal Circuit Court of Appeals. Based on this decision, management believes that the Company's ability to obtain any recovery with respect to the claim is remote.

Litigation

On August 9, 2009, Sparton and certain subsidiaries were named as defendants in a wrongful death suit, alleging that a defective transmission shifter assembly in a 1996 Chrysler automobile caused a July 2007 death. The suit also named Chrysler LLC, Dura Automotive Systems, Inc., and Chandler Motors Company as defendants. The suit was filed in Pontotoc County Circuit Court in Mississippi. Sparton has not manufactured automotive shifter assemblies for Chrysler since December 1996, when it sold its KPI Group subsidiary to Dura Automotive Systems, Inc. The plaintiff seeks damages from the defendants for economic loss, pain and suffering, and loss of companionship, as well as punitive damages. Sparton has denied liability, has notified its insurance carriers regarding this claim, and is vigorously defending this matter. At this time, it is not possible to determine or predict the outcome of this suit, and as a result, no amounts have been accrued in the financial statements as of December 31, 2010. While no assurances can be given, the Company does not believe that this litigation, if adversely determined, would have a material adverse affect on the Company's financial position or results of operations.

Other

In addition to the foregoing, from time to time, the Company is involved in various legal proceedings relating to claims arising in the ordinary course of business. The Company is not currently a party to any other such legal proceedings, the adverse outcome to which, individually or in the aggregate, is expected to have a material adverse effect on our business, financial condition or results of operations.

Contractual Obligations and Off-Balance Sheet Arrangements

Information regarding the Company's long-term debt obligations, environmental liability payments, operating lease payments, and other commitments is provided in Part II, Item 7, Management's Discussion and Analysis of Financial Condition and Results of Operations, of the Company's Annual Report on Form 10-K for the fiscal year ended June 30, 2010. As discussed in Note 2 to the Unaudited Condensed Consolidated Financial Statements in this Quarterly Report, concurrent with the August 2010 acquisition of certain assets of the contract manufacturing business of Delphi Medical Systems, LLC, the Company entered into a lease of the facility housing the operations of this contract manufacturing business. Due primarily to the lease of this new facility, contractual obligations under operating leases are now \$1,094,000, \$1,794,000, \$1,096,000, \$714,000, \$718,000 and \$1,555,000 for fiscal years 2011, 2012, 2013, 2014, 2015 and thereafter, respectively. In addition, as of June 30, 2010, there were \$16.6 million of non-cancelable purchase orders outstanding. This amount has increased to \$25.4 million as of December 31, 2010. Other than as noted above, there have been no material changes in the nature or amount of the Company's contractual obligations since June 30, 2010.

Critical Accounting Policies

Our financial statements are prepared in conformity with GAAP and require us to select appropriate accounting policies. The assumptions and judgments we use in applying our accounting policies have a significant impact on our reported amounts of assets, liabilities, revenue and expenses. While we believe that the assumptions and judgments used in our estimates are reasonable, actual results may differ from these estimates under different assumptions or conditions.

Table of Contents

We have identified the most critical accounting policies upon which our financial status depends. The critical policies were determined by considering accounting policies that involve the most complex or subjective decisions or assessments. We also have other policies considered key accounting policies; however, these policies do not meet the definition of critical accounting policies because they do not generally require us to make estimates or judgments that are complex or subjective. Our critical accounting policies include the following:

Environmental contingencies

Government contract cost estimates

Commercial inventory valuation allowances

Allowances for probable losses on receivables

Pension obligations

Business combinations

Valuation of property, plant and equipment

Goodwill and customer relations

Income taxes

Restructuring accrual

Stock-based compensation

There have been no significant changes to our critical accounting policies that are described in Part II, Item 7, "Management's Discussion and Analysis of Financial Condition and Results of Operations" section of our Annual Report on Form 10-K for the year ended June 30, 2010.

New Accounting Pronouncements

See Note 17, Summary of Significant Accounting Policies, of the "Notes to Unaudited Condensed Consolidated Financial Statements" in this Quarterly Report on Form 10-Q for a discussion of new accounting pronouncements.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

The Company manufactures its products in the United States and Vietnam. Sales are to the U.S. as well as foreign markets. The Company is potentially subject to foreign currency exchange rate risk relating to intercompany activity and balances and to receipts from customers and payments to suppliers in foreign currencies. Also, adjustments related to the translation of the Company's Vietnamese financial statements into U.S. dollars are included in current earnings. As a result, the Company's financial results could be affected by factors such as changes in foreign

Edgar Filing: SPARTON CORP - Form 10-Q

currency exchange rates or economic conditions in the domestic and foreign markets in which the Company operates. However, minimal third party receivables and payables are denominated in foreign currency and the related market risk exposure is considered to be immaterial.

The Company's revolving credit line, if drawn upon, is subject to future interest rate fluctuations which could potentially have a negative impact on cash flows of the Company. The Company is not party to any currency exchange or interest rate protection agreements as of December 31, 2010.

Item 4. Controls and Procedures.

Each of our Chief Executive Officer and Chief Financial Officer has evaluated the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities and Exchange Act of 1934) as of the end of the period covered by this quarterly report. Based on such evaluation, such officers have concluded that, as of the end of the period covered by this quarterly report, our disclosure controls and procedures are effective.

There have been no changes in our internal controls over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended December 31, 2010 that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.

Table of Contents

PART II. OTHER INFORMATION

Item 1. Legal Proceedings.

See Management's Discussion and Analysis of Financial Condition and Results of Operations - Commitments and Contingencies of this report.

In addition to the above, from time to time, we are involved in various legal proceedings relating to claims arising in the ordinary course of business. We are not currently a party to any such legal proceedings, the outcome of which, individually or in the aggregate, is expected to have a material adverse effect on our business, financial condition or results of operations.

Item 1A. Risk Factors.

You should carefully consider the risks and uncertainties described in Part I, Item 1A. Risk Factors in our Annual Report on Form 10-K for the year ended June 30, 2010 as well as other information in our subsequent filings with the SEC, including this Quarterly Report on Form 10-Q. Our business, financial condition, results of operations and stock price could be materially adversely affected by any of these risks. The risks described in our Annual Report on Form 10-K and our subsequent filings are not the only ones we face. Additional risks and uncertainties that are currently unknown to us or that we currently consider to be immaterial may also impair our business or adversely affect our financial condition, results of operations and stock price.

Table of Contents**Item 6. Exhibits.**

| Exhibit | |
|----------------|---|
| Number | Description |
| 3.1 | Second Amended Articles of Incorporation of the Registrant, incorporated herein by reference from the Registrant's Proxy Statement on Form DEF 14A filed with the SEC on September 21, 2010. |
| 3.2 | Amended and Restated Code of Regulations of the Registrant, incorporated herein by reference from the Registrant's Proxy Statement on Form DEF 14A filed with the SEC on September 21, 2010. |
| 10.1 | Amended and Restated Revolving Credit and Security Agreement dated August 14, 2009 among the Company, its subsidiaries and National City Business Credit, Inc., incorporated by reference from Exhibit 10.1 to the Registrant's Current Report on Form 8-K filed with the SEC on August 18, 2009. |
| 10.2 | Post-closing Agreement dated August 14, 2009 among the Company, its subsidiaries and National City Business Credit, Inc., incorporated by reference from Exhibit 10.2 to the Registrant's Current Report on Form 8-K filed with the SEC on August 18, 2009. |
| 10.3 | Long-Term Stock Option Incentive Plan, incorporated by reference from Exhibit 10.1 to the Registrant's Current Report on Form 8-K filed with the SEC on September 11, 2009. |
| 10.4 | Lease Extension and Amendment Agreement dated May 1, 2010 between Sparton Technology, Inc. and 9621 Coors, L.L.C., guaranteed by Albuquerque Motor Company, Inc., incorporated by reference from Exhibit 10.1 to the Registrant's Current Report on Form 8-K filed with the SEC on May 6, 2010. |
| 10.5 | Option Agreement dated May 1, 2010 by and between Sparton Technology, Inc. and 9621 Coors, L.L.C., guaranteed by Albuquerque Motor Company, Inc., incorporated by reference from Exhibit 10.2 to the Registrant's Current Report on Form 8-K filed with the SEC on May 6, 2010. |
| 10.6 | Asset Purchase Agreement dated July 9, 2010 between Delphi Medical Systems, LLC and Sparton Medical Systems Colorado, LLC, incorporated by reference from Exhibit 10.1 to the Registrant's Current Report on Form 8-K filed with the SEC on July 12, 2010. |
| 10.7 | Asset Purchase Agreement dated December 8, 2010 between Coven Holdings LLC and Sparton Technology, Inc., incorporated by reference from Exhibit 10.1 to the Registrant's Current Report on Form 8-K filed with the SEC on December 14, 2010. |
| 31.1* | Chief Executive Officer certification under Section 302 of the Sarbanes-Oxley Act of 2002. |
| 31.2* | Chief Financial Officer certification under Section 302 of the Sarbanes-Oxley Act of 2002. |
| 32.1* | Chief Executive Officer and Chief Financial Officer certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |

* Filed herewith.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Sparton Corporation

Date: February 9, 2011

By: /s/ CARY B. WOOD
Cary B. Wood
President and Chief Executive Officer
(Principal Executive Officer)

Date: February 9, 2011

By: /s/ GREGORY A. SLOME
Gregory A. Slome
Senior Vice President and Chief Financial Officer
(Principal Financial Officer)